Books by Subject
- A to Z drug facts — Development of innovative drugs via modeling with MATLAB : a practical guide (135)
- Development of novel vaccines : skills, knowledge, and translational technologies — Kidney-- toxicological assessment (135)
- Kinase inhibitors : methods and protocols — Pharmacological treatment of mental disorders in primary health care (135)
- Pharmacology : PreTest self-assessment and review. 12th ed. — WHO guidelines on safety monitoring of herbal medicines in pharmacovigilance systems (133)
- 2012 Springer Protocolsedited by Bernhard Kuster.Targeting cancer with small-molecular-weight kinase inhibitors / Doriano Fabbro [and others] -- Small-molecule protein and lipid kinase inhibitors in inflammation and specific models for their evaluation / Matthias Gaestel and Alexey Kotlyarov -- Measuring the activity of leucine-rich repeat kinase 2 : a kinase involved in Parkinson's disease / Byoung Dae Lee [and others] -- Measuring P13K lipid kinase activity / Elisa Ciraolo, Alessia Perino, and Emilio Hirsch -- A fluorescence polarization assay for the discovery of inhibitors of the polo-box domain of polo-like kinase 1 / Wolfgang Reindl, Klause Strebhardt, and Thorsten Berg -- Assessment of hepatotoxicity potential of drug candidate molecules including kinase inhibitors by hepatocyte imaging assay technology and bile flux imaging assay technology / Jinghai J. Xu [and others] -- Kinase inhibitor selectivity profiling using differential scanning fluorimetry / Oleg Fedorov, Frank H. Niesen, and Stefan Knapp -- Chemoproteomic characterization of protein kinase inhibitors using immobilized ATP / James S. Duncan, Timothy A.J. Haystead, and David W. Litchfield -- Proteome-wide identification of staurosporine-binding kinases using capture coumpound mass spectrometry / Jenny J. Fischer, Olivia Y. Graebner (neé Baessler), and Mathias Dreger -- Affinity pruification of proteins binding to kinase inhibitors immobilized on self-assembling monolayers / Marcus Bantscheff, Scott Hobson, and Bernhard Kuster -- Kinase inhibitor profiling using chemoproteomics / Markus Schirle [and others] -- Covalent cross-linking of kinases with their corresponding peptide substrates / Alexander V. Statsuk and Kevan M. Shokat -- Receptor tyrosine kinase inhibitor profiling using bead-based multiplex sandwich immunoassays / Oliver Pötz [and others] -- Monitoring phosphoproteomic response to targeted kinase inhibitors using reverse-phase protein microarrays / Gabriela Lavezzari and Mark R. Lackner -- Measuring phosphorylation-specific changes in response to kinase inhibitors in mammalian cells using quantitative proteomics / Nurhan Özlü, Marc Kirchner, and Judith Jebanathirajah Steen -- Investigation of acquired resistance to EGFR-targeted therapies in lung cancer using cDNA microarrays / Kian Kani, Rafaella Sordella, and Parag Mallick.
- 2012 Springer Protocolsedited by Loralie J. Langman and Chistine L.H. Snozek.Introduction to drug testing : the expanding role of mass spectrometry / Catherine Hammett-Stabler and Steven W. Cotten -- LC-MS vs. GC-MS, online extraction systems, advantages of technology for drug screening assays / Pierre Marquet -- LC-MS/MS techniques for high-volume screening of drugs of abuse and target drug quantitation in urine/blood matrices / Jeff C. Eichhorst [and others] -- Benzodiazepines and metabolites from biological fluids by liquid chromatography electrospray tandem mass spectrometry / Cynthia L. Morris-Kukoski, Jason E. Schaff, and Louis J. Reda -- Opiate screening and quantitation in urine/blood matrices using LC-MS/MS techniques / Jeff C. Eichhorst [and others] -- Synthetic opioid analysis by LC-MS/MS / David M. Garby and Lynn A. Cheryk -- Determination of cannabinoids using liquid chromatography with mass spectrometric detection / Oscar Quintela and Dennis J. Crouch -- Cocaine and metabolites by LC-MS/MS / Christine L.H. Snozek, Matthew W. Bjergum, and Loralie J. Langman -- Quantitation of amphetamine-type stimulants by LC-MS/MS / Robert A. Middleberg and Joseph Homan -- Detection of prohibited substances by liquid chromatography tandem mass spectrometry for sports doping control / Brian D. Ahrens, Borislav Starcevic, and Anthony W. Butch -- LC-MS/MS screen for xenobiotics and metabolites / Francois-Ludovic Sauvage and Pierre Marquet -- Qualitative identification of rodenticide anticoagulants by LC-MS/MS / Robert A. Middleberg and Joseph Homan -- Hypoglycemic agent screening by LC-MS/MS / Eric W. Korman, Loralie J. Langman, and Christine L.H. Snozek -- LC-MS/MS method for the detection of common laxatives / Robert A. Middleberg and Joseph Homan -- Simultaneous determination of cyclosporine, sirolimus, and tacrolimus in whole blood using liquid chromatography-tandem mass spectrometry / Uttam Garg, Ada Munar, and C. Clinton Frazee III -- Quantification of tricyclic antidepressants using UPLC-MS/MS / Kamisha L. Johnson-Davis [and others] -- Quantitation of first- and second-generation antipsychotics by LC-MS/MS / Elizabeth R. Kiely and Heather M. Antonides -- Analysis of selected anticonvulsants by high performance liquid chromatography-tandem mass spectrometry / Jennifer A. Collins and Gregory C. Janis -- Therapeutic drug monitoring of tamoxifen using LC-MS/MS / Simone M. Tchu, Kara L. Lynch, and Alan H.B. Wu.
- 2006 ScienceDirect[edited by] Mahmud T.H. Kahn, Arjumand Ather.Reverse pharmacognosy : a new concept for accelerating natural drug discovery / Quoc-Tuan Do and Philippe Bernard -- Effects of plant extracts on gene expression profiling : from macroarrays to microarray technology / Carlo Mischiati, Alessia Sereni, Mahmud Tareq Hassan Khan, Ilaria Lampronti and Roberto Gambari -- Effects of medicinal plant extracts on molecular interactions between DNA and transcription factors / Ilaria Lampronti, Mahmud Tareq Hassan Khan, Nicoletta Bianchi, Giordana Feriotto, Carlo Mischiati, Monica Borgatti and Roberto Gambari -- Plants with antitumor properties : from biologically active molecules to drugs / Ilaria Lampronti, Mahmud Tareq Hassan Khan, Nicoletta Bianchi, Elisabetta Lambertini, Roberta Piva, Monica Borgatti and Roberto Gambari -- Herbal extracts and compounds active against herpes simplex virus / Kenneth D. Thompson -- Pharmacological modulation of cough reflex / Gabriela Nosalova, Juraj Mokry and Sona Franova -- Phytotherapy of cough / Sona Franova, Gabriela Nosalova and Juraj Mokry -- The medicinal potential of black seed (Nigella sativa) and its components / Hala Gali-Muhtasib, Nahed El-Najjar and Regine Schneider-Stock -- Cyclin-dependent kinase inhibitors from natural sources : recent advances and future prospects for cancer treatment / Hala Gali-Muhtasib -- Anticancer and medicinal properties of essential oil and extracts of East Mediterranean sage (salvia triloba) / Hala Gali-Muhtasib -- Marine organisms from Brazil as source of potential anticancer agents / Letícia Veras Costa-Lotufo, Cláudia Pessoa, Maria Elisabete A. Moraes, Adaíla Marta Paixão Almeida, Manoel Odorico de Moraes and Tito Monteiro da Cruz Lotufo -- Anticancer potential of Northeast Brazilian plants / Cláudia Pessoa, Letícia Veras Costa-Lotufo, Albert Leyva, Maria Elisabete Amaral de Moraes and Manoel Odorico de Moraes -- Safety and efficacy of phytomedicines / Manoel Odorico de Moraes, Fernando Antônio Frota Bezerra, Letícia Veras Costa-Lotufo, Cláudia Pessoa and Maria Elisabete Amaral de Moraes -- Pharmacological and biochemical profiling of lead compounds from traditional remedies : the case of Croton cajucara / Maria Aparecida M. Maciel, Tereza Neuma C. Dantas, Janaína Keila P. Câmara, Angelo C. Pinto, Valdir F. Veiga Jr., Carlos R. Kaiser, Nuno A. Pereira, Cristina M.T.S. Carneiro, Frederico A. Vanderlinde, Antônio J. Lapa, Aniele R. Agner, Ilce M.S. Cólus, Juliana Echevarria-Lima, Noema F. Grynberg, Andressa Esteves-Souza, Kenia Pissinate and Aurea Echevarria -- Antihypertensive peptides from natural resources / Toshiro Matsui and Kiyoshi Matsumoto -- Xanthones as therapeutic agents : chemistry and pharmacology / Noungoue Tchamo Diderot, Ngouela Silvere and Tsamo Etienne -- Inhibition of immunodeficiency type-1 virus (HIV-1) life cycle by medicinal plant extracts and plant-derived compounds / Roberto Gambari and Ilaria Lampronti -- Anticancer properties of saffron, Crocus sativus Linn. / José-Antonio Fernández -- Lead compounds and drug candidates from some Turkish plants for human health / İlkay Orhan and Bilge Şener -- Molecular design of multifunctional anti-Salmonella agents based on natural products / Isao Kubo, Ken-ichi Fujita, Ken-ichi Nihei and Aya Kubo -- Plant growth inhibitory activities by secondary metabolites isolated from Latin American flora / Carlos L Céspedes, Juan C Marín, Mariana Domínguez, J Guillermo Avila and Blanca Serrato -- Metabolomics : systematic studies of the metabolic profiling / Mahmud Tareq Hassan Khan and Arjumand Ather.
- Lead optimization for medicinal chemists : pharmacokinetic properties of functional groups and organic compounds2012 WileyFlorencio Zaragoza Dorwald.Part I : Introduction. The drug discovery process ; lead optimization -- Part II : The pharmacokinetic properties of compound classes. Alkanes ; Alkenes and alkynes ; Arenes ; Halides ; Azides ; Nitro compounds ; Azo compounds ; Triazenes ; Nitrates and nitrites ; N-nitroso compounds ; N-oxides ; Alcohols ; Phenols ; Ethers ; Epoxides ; Peroxides ; Thiols ; Thioethers ; Sulfoxides ; Sulfones ; Aliphatic amines ; Quaternary ammonium salts ; Amidines ; Guanidines, acylguanidines, and biguanides ; Anilines ; Hydrazines, acylhydrazines, and hydrazones ; Aldehydes ; Ketones ; Carboxylic acids ; Carboxylic esters ; Amides ; Lactams and imides ; Nitriles ; Carbonates ; Carbamates ; Ureas ; Thiocarbonyl compounds ; Sulfonic acids ; Sulfonic esters ; Sulfates And sulfamic acids ; Phosphonic acids ; Phosphoric acid derivatives ; N-(aminoalkyl)benzamides, -benzoates, and related compounds ; Arylalkylamines ; Phenethylamines (2-phenylethylamines) ; Aminoalkylindoles and indole alkaloids ; Phenothiazines ; Dibenzazepines and related tricyclic compounds ; 3-aryloxy-2-hydroxypropylamines (b-adrenergic antagonists; 'b-blockers') ; Opiates ; N-(carboxyalkyl)-a-amino acid amides (prils) ; Anilides and amides of glycine ; Peptides, peptidomimetics, and related oligoamides ; Oligoarylamines, oligoarylamides, oligoarylcarbamates, and oligoarylureas ; Imidazoles ; Triazoles ; Pyridines, pyrimidines, and related compounds ; Quinolines ; Nucleoside analogs ; Dihydropyridines ; Arenesulfonamides ; Sulfonylureas ; Benzodiazepines ; Steroids ; Anthracyclines ; Arylacetic, benzoic, and related carboxylic acids (NSAIDS) ; Quinolonecarboxylic acids (gyrase inhibitors) ; B-lactams ; Prostaglandin analogs ; Sartans ; Statins ; Folic acid analogs (antifolates) ; Taxanes ; Macrocyclic compounds.
- Leading pharmaceutical innovation : trends and drivers for growth in the pharmaceutical industry. 2nd ed.2008 SpringerOliver Gassmann, Gerrit Reepmeyer, Maximilian von Zedtwitz.
- 2006Richard D. Howland, Mary J. Mycek ; editors, Richard A. Harvey, Pamela C. Champe.Status: Not Checked OutLane Catalog Record
- 2009Richard Finkel, Michelle A. Clark, Luigi X. Cubeddu.Status: Not Checked OutLane Catalog Record
- 2015 SpringerRaymond Chuen-Chung Chang, Kwok-Fai So, editors.1. Chemical and genetic diversity of Wolfberry -- 2. Immunoregulation and Lycium Barbarum -- 3. The antioxidant, anti-inflammatory, and antiapoptotic effects of Wolfberry in fatty liver disease -- 4. Effectts of Lycium barbarum on modulation of blood vessel and hemodynamics -- 5. Dermatologic uses and effects of Lycium barbarum -- 6. Lycium Barbarum and tumors in the gastrointestinal tract -- 7. Prevention of neurodegeneration for Alzheimer's disease by Lycium barbarum -- 8. Prosexual effects of Lycium Barbarum -- 9. Lycium Barbarum: neuroprotective effects in ischemic stroke -- 10. Secondary degeneration after partial optic nerve injury and possible neuroprotective effects of Lycium Barbarum (Wolfberry) -- 11. Role of Lycium Barbarum extracts in retinal diseases -- 12. Allergenic sensitisation mediated by Wolfberry.
- 2010 SpringerL. Harivardhan Reddy, Patrick Couvreur, editors ; foreword by Rakesh K. Jain.Part 1. Classification, Opportunities and Challenges -- Classification of Anticancer Drugs Based on Therapeutic Targets -- Signal Transduction Pathways as Therapeutic Targets in Cancer Therapy -- Part 2. Polymer-Based Anticancer Prodrugs -- HPMA-Anticancer Drug Conjugates -- Poly-l-Glutamic Acid Anti-cancer Drug Conjugates -- Polysaccharide-Based Anticancer Prodrugs -- PEG-Anticancer Drugs -- Poly(ethylene glycol)-Protein, Peptide, and Enzyme Conjugates -- Part 3. Lipid-Based -- Anticancer Prodrugs -- Lipid-Based Anticancer Prodrugs -- Part 4. Antibody-Directed Cancer Therapy -- Antibody-Cytotoxic Compound Conjugates for Oncology -- Immunoconjugate Anticancer Therapeutics -- Antibody-Directed Enzyme Prodrug Therapy (ADEPT) for Cancer -- EGFR-Directed Monoclonal Antibodies -- The Biology of the HER Family and Her2/neu Directed-Antibody Therapy -- Anti-Vascular Endothelial Growth Factor Monoclonal Antibodies -- Monoclonal Antibody Therapy for Hematologic Malignancies -- Part 5. Anticancer Oligonucleotide Therapeutics -- Anticancer Oligonucleotides -- Part 6. Miscellaneous -- New Molecular Therapeutic Interventions: The Case of Breast Cancers.
- v. 1-2, 2014 Springerv. 2 SpringerBernd Nilius, Veit Flockerzi, editors.v. 1. TRPs: truly remarkable proteins -- The TRCP subfamily -- TRPC1 -- TRPC2 -- TRPC3: a multifunctional signaling molecule -- TRPC4 and TRPC4-containing channels -- TRPC5 -- TRPC6: physiological function and pathophysiological relevance -- Transient receptor potential canonical 7 (TRPC7) -- The TRPV subfamily -- TRPV1 -- TRPV2 -- TRPV3 -- The TRPV4 channel -- TRPV5, a Ca2+ channel for the fine tuning of Ca2+ reabsorption -- TRPV6 channels -- The TRPM subfamily -- TRPM1 -- TRPM2 -- TRPM3 -- TRPM4 -- TRPM5 -- TRPM6 -- TRPM7 -- TRPM8 -- The TRPA1, TRPML and TRPP subfamily -- TRPA1 -- TRPML1: an ion channel in the lysosome -- TRPML2 and mucolipin evolution -- TRPML3 -- TRPP subfamily and polycystin-1 proteins -- v. 2. TRPs as special cell sensors -- Temperature sensing with TRPs -- TRPs in mechano-sensing and volume regulation -- TRPs as chemosensors (ROS, RNS, RCS, gasotransmitters) -- Photosensitive TRPs -- TRPs in taste and chemesthesis -- TRPs and Pain -- TRPs in hearing -- TRPs in olfaction -- General topics -- Evolutionary conserved, multitasking TRP channels-lessons from worms and flies -- Structural biology of TRP channels -- High-resolution views of TRPV1 and their implications for the TRP channel superfamily -- Physiological functions and regulation of TRPC channels -- The TRPCs-STIM1-orai interaction -- The TRPC family of TRP channels: roles inferred (mostly) from knockout mice and relationship to ORAI proteins -- TRPs: modulation by drug-like compounds -- TRP channels in reproductive (neuro)endocrinology -- Modulation of TRP ion channels by venomous toxins -- Phosphoinositide regulation of TRP channels -- TRP modulation by natural compounds -- What do we really know and what do we need to know: some controversies, perspectives, and surprises.
- 2016 SpringerRudolph M. Navari, editor.1. Introduction -- 2. The physiology and pharmacology of nausea and vomiting induced by anticancer chemotherapy in humans -- 3. First-generation 5-HT3 receptor antagonists -- 4. Palonosetron -- 5. The role of neurokinin-1 receptor antagonists in CINV -- 6. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting -- 7. Gabapentin for the prevention of CINV -- 8. Prevention of CINV in patients receiving high-dose multiple-day chemotherapy -- 9. Clinical management of CINV -- 10. Treatment of chemotherapy-induced nausea -- 11. Conclusions -- 12. Future directions.
- 2005 Springer Protocolsedited by Emmanuel S. Onaivi.
- 2007 Springeredited by Mahmoud A. ElSohly.Cannabis and natural cannabis medicines / Robert C. Clarke and David P. Watson -- Chemistry and analysis of phytocannabinoids and other cannabis constituents / Rudolf Brenneisen -- Chemical fingerprinting of cannabis as a means of source identification / Mahmoud A. ElSohly, Donald F. Stanford, and Timothy P. Murphy -- Marijuana smoke condensate: chemistry and pharmacology / Hala N. ElSohly and Mahmoud A. ElSohly -- Pharmacology of cannabinoids / Lionel P. Raymon and H. Chip Walls -- The endocannabinoid system and the therapeutic potential of cannabinoids / Billy R. Martin -- Immunoassays for the detection of cannabis abuse: technologies, development strategies, and multilevel applications / Jane S-C. Tsai -- Mass spectrometric methods for determination of cannabinoid physiological specimens / Rodger L. Foltz -- Human cannabinoid pharmacokinetics and interpretation of cannabinoid concentrations in biological fluids and tissues / Marilyn A. Huestis and Michael L. Smith -- Medical and health consequences of marijuana / Jag H. Khalsa -- Effects of marijuana on the lung and immune defenses / Donald P. Tashkin and Michael D. Roth -- Marijuana and driving impairment / Barry K. Logan -- Postmortem considerations / Steven B. Karch -- Cannabinoid effects on biopsychological, neuropsychiatric and neurological processes / Richard E. Musty.
- 2013 Wileyedited by Walter A. Korfmacher.1. Overview of the various types of mass spectrometers that are used in drug discovery and drug development / Gerard Hopfgartner -- 2. Utility of high resolution mass spectrometry for new drug discovery applications / William Bart Emary and Nanyan Rena Zhang -- 3. Quantitative mass spectrometry considerations in a regulated environment / Mohammed Jemal and Yuan-Qing Xia -- 4. Mass spectrometry for quantitative in vitro ADME assays / Jun Zhang and Wilson Z. Shou -- 5. Metabolite identification using mass spectrometry in drug development / Natalia Penner, Joanna Zgoda-Pols, and Chandra Prakash -- 6. MS analysis of biological drugs, proteins, and peptides / Yi Du, John Mehl, and Pavlo Pristatsky -- 7. Characterization of impurities and degradation products in small molecule pharmaceuticals and biologics / Hui Wei, Guodong Chen and Adrienne A. Tymiak -- 8. Liquid extraction surface analysis (LESA) : a new mass spectrometry-based technique for ambient surface profiling / Dan Eikel and Jack Henion -- 9. MS applications in support of medicinal chemistry sciences / Maarten Honing, Benno Ingelse, and Birendraÿ N. Pramanik -- 10. Imaging mass spectrometry of proteins and peptides / Michelle L. Reyzer and Richard M. Caprioli -- 11. Imaging mass spectrometry for drugs and metabolites / Stacey R. Oppenheimer -- 12. Screening reactive metabolites : role of liquid chromatography-high resolution mass spectrometry in combination with 'intelligent' data mining tools / Shuguang Ma and Swapan K. Chowdhury -- 13. Mass spectrometry of siRNA / Mark Cancilla and Mike Flanagan -- 14. Mass spectrometry for metabolomics / Petia Shipkova and Michael D. Reily -- 15. Quantitative analysis of peptides with mass spectrometry : selected reaction monitoring or high resolution full scan? / Lieve Dillen and Filip Cuyckens.
- 2011 Springer Protocolsedited by Jerry Zweigenbaum.European union regulations / Peter Furst -- China's food safety regulation and mass spectrometry / Xiaogang Chu [and others] -- United States and Japanese food regulations / Jerry Zweigenbaum -- QuEChERS sample preparation approach for mass spectrometric analysis of pesticide residues in foods / Steven J. Lehotay -- Automated solid phase extraction / Norbert Helle, Meike Baden, and Kaj Petersen -- Multiresidue pesticide analysis by capillary gas chromatography-mass spectrometry / Jon W. Wong [and others] -- Targeted pesticide residue analysis using triple quad LC-MS/MS / Lutz Alder -- LC/TOF-MS analysis of pesticides in fruits and vegetables : the emerging role of accurate mass in the unambiguous identification of pesticides in food / Imma Ferrer, E. Michael Thurman, and Jerry Zweigenbaum -- Hormone analysis in food products / Marco H. Blokland and Saskia S. Sterk -- Analysis of multiple mycotoxins in food / Jana Hajslova, Milena Zachariasova, and Tomas Cajka -- Multi mycotoxin analysis in food products using immunoaffinity extraction / Masahiko Takino, Hiroki Tanaka, and Toshitsugu Tanaka -- Multiresidue analysis of antibiotics in food of animal origin using liquid chromatography-mass spectrometry / Katerina Mastovska -- LC-MS/MS methods for the determination of specific antibiotics residues in food matrices / Gui-Liang Chen and Yan-Yan Fang -- Identification of unknown migrants from food contact materials / Malcolm Driffield [and others] -- Halogenated persistent organic pollutants and polycyclic aromatic hydrocarbons in food / Tomas Cajka and Jana Hajslova.
- 2007 Springer[edited by] Alan R. Saltiel, Jeffrey E. Pessin.Insulin and IGF-I receptor structure and binding mechanism / Pierre de Meyts ... [et al.] -- Subcellular compartmentalization of insulin signaling processes and GLUT4 trafficking events / Robert T. Watson ... [et al.] -- Regulation of insulin action and insulin secretion by snare-mediated vesicle exocytosis / Debbie C. Thurmond -- Control of protein synthesis by insulin / Joseph F. Christian and John C. Lawrence -- Hepatic regulation of fuel metabolism / Catherine Clark and Christopher B. Newgard -- Insulin action gene regulation / Calum D. Sutherland, Richard M. O'Brien, and Daryl K. Granner -- Insulin action in the islet B-cell / Rohit N. KulkarnI -- Central regulation of insulin sensitivity / Silvana Obici and Luciano Rossetti -- Transgenic models of impaired insulin signaling / Francesco Oriente and Domenico Accili -- Insulin resistance / C. Hamish Courtney and Jerrold M. Olefsky.
- 2014 ClinicalKeyDerek G. Waller, Anthony P. Sampson.Principles of pharmacology and mechanisms of drug action -- Principles of pharmacology and mechanisms of drug action -- Drug discovery, safety and efficacy -- Neurotransmission and the peripheral autonomic nervous system -- Ischaemic heart disease -- Systemic and pulmonary hypertension -- Heart failure -- Cardiac arrhythmias -- Cerebrovascular disease and dementia -- Peripheral vascular disease -- Haemostasis -- Asthma and chronic obstructive pulmonary disease -- Respiratory disorders : cough, respiratory stimulants, cystic fibrosis and neonatal respiratory distress syndrome -- Diuretics -- Disorders of micturition -- Erectile dysfunction -- General anaesthetics -- Local anaesthetics -- Opioid analgesics and the management of pain -- Anxiolytics, sedatives and hypnotics -- The major psychotic disorders : schizophrenia and mania -- Depression, attention deficit hyperactivity disorder and narcolepsy -- Epilepsy -- Extrapyramidal movement disorders and spasticity -- Other neurological disorders : multiple sclerosis, motor neuron disease and Guillain - Barre syndrome -- Migraine and other headaches -- The neuromuscular junction and neuromuscular blockade -- Myasthenia gravis -- Non-steroidal anti-inflammatory drugs -- Rheumatoid arthritis, other inflammatory arthritides and osteoarthritis -- Hyperuricaemia and gout -- Nausea and vomiting -- Dyspepsia and peptic ulcer disease -- Inflammatory bowel disease -- Constipation, diarrhoea and irritable bowel syndrome -- Liver disease -- Obesity -- The immune response and immunosuppressant drugs -- Antihistamines and allergic disease -- Diabetes mellitus -- The thyroid and control of metabolic rate -- Calcium metabolism and metabolic bone disease -- Pituitary and hypothalamic hormones -- Corticosteroids (glucocorticoids and mineralocorticoids) -- Female reproduction -- Androgens, anti-androgens and anabolic steroids -- Anaemia and haematopoietic colony-stimulating factors -- Lipid disorders -- Skin disorders -- The eye -- Chemotherapy of infections -- Chemotherapy of malignancy -- Drug toxicity and overdose -- Substance abuse and dependence -- Prescribing, adherence and information about medicines -- Drug therapy in special situations.
- Medicalization of cannabis : the transcript of a Witness Seminar held by the Wellcome Trust Centre for the History of Medicine at UCL, London, on 24 March 20092010 Wellcome Trustedited by S.M Crowther, L.A. Reynolds and E.M. Tansey.
- 2015 SpringerSven Otto, editor.Osteonecrosis of the jaws is a well-known side-effect of antiresorptive therapy that predominantly occurs in patients suffering from malignant diseases and receiving intravenous administrations of nitrogen-containing bisphosphonates or subcutaneous administrations of denosumab, a monoclonal antibody. Less frequently it may also be observed in patients with osteoporosis who are being treated with these antiresorptive drugs. This textbook provides detailed, up-to-date information on all aspects of medication-related osteonecrosis of the jaws, including clinical features, pathogenesis, treatment options, and preventive measures. It also explains safe prevention and treatment strategies for patients receiving antiresorptive drugs who require extractions, implant insertions, and other dento-alveolar surgeries. This book will be of major interest for medical and dental students, dentists, and oral and maxillofacial surgeons as well as osteologists and oncologists.
- 2005 MyiLibraryThomas Nogrady, Donald F. Weaver.Also available: Print – 2005
- 2006 CRCnetBASEM. Daniel.A unified and single-source reference book providing significant data on a wide spectrum of medicinal herbs practiced worldwide and their chemical ingredients. 350 plants are dealt with in detail dovetailing their distinguishing botanical characters, chemical components and biomarkers of all the useful parts, authentic medicinal properties and the pharmacological actions they elicit. Constituent compounds have been grouped according to their natural product classification. This book is intended to oncompass an in-depth coverage of the chemistry of "Plant Products" such as alkaloids, terponoids, phenolics, etc. Emerging trends like aromatherapy and antioxidant therapy are discussed and a user's guide is appended at the end.--excerpted from book jacket.
- 2012 CRCnetBASEeditors, Mahendra Rai, Geofffrey A. Cordell, Jose L. Martinez, Mariela Marinoff, Luca Rastrelli.New strategies for traditional medicine -- Developing better herbal medicines in the post-genomic era -- Revitalization of the knowledge of herbs: a way forward to discovery of new drugs -- Ethnobotanical uses of the native flora from Brazilian north-eastern region -- Diversity and uses of the genus croton (euphorbiaceae) in Northeastern Brazil -- Ethnomedical knowledge among the "Quilombolas" from the Amazon region of Brazil with a special focus on plants used as nervous system tonics -- Advances in the knowledge of medicinal plants in Eastern Andalusia, Spain -- Tropical propolis: recent advances in chemical components and Botanical origin -- Anti-malarial plants used in folk medicine in Bangladesh -- Usnea sulcata motyka: an ethnomycological review of its use in traditional medicine -- Sirukurinjan: An ancient remedy for a modern incurable disease, diabetes -- Herbal drugs used for domestic animals -- Endophytes from medicinal plants as novel sources of bioactive compounds -- Advances in medicinal plants with antitumoral activity -- Medicinal plants: how are they used to treat neurological diseases? -- Inflammatory diseases: mechanisms and natural remedies -- Recent advances to evaluate anti-diabetic medicinal plants -- Botanical origin and Biological activity of propolis -- Bioactivity of plant essential oils -- Antibacterial and antiviral effects of aromatic plant-derived essential oils: a scientific and medicinal approach -- Strategies of solvent system selection for the isolation of natural products by countercurrent chromatography.
- 2006 CRCnetBASEChristophe Wiart.Medicinal plants classified in the family Annonaceae -- Medicinal plants classified in the family Myristicaceae -- Medicinal plants classified in the family Lauraceae -- Medicinal plants classified in the family Piperaceae -- Medicinal plants classified in the family Aristolochiaceae -- Medicinal plants classified in the family Nympheaceae -- Medicinal plants classified in the family Menispermaceae -- Medicinal plants classified in the family Polygonaceae -- Medicinal plants classified in the family Myrsinaceae -- Medicinal plants classified in the family Ebenaceae -- Medicinal plants classified in the family Bombacaceae -- Medicinal plants classified in the family Elaeocarpaceae -- Medicinal plants classified in the family Capparaceae -- Medicinal plants classified in the family Flacourtiaceae -- Medicinal plants classified in the family Passifloraceae -- Medicinal plants classified in the family Cucurbitaceae -- Medicinal plants classified in the family Connaraceae -- Medicinal plants classified in the family Anisophylleaceae -- Medicinal plants classified in the family Rosaceae -- Medicinal plants classified in the family Thymeleaceae -- Medicinal plants classified in the family Melastomataceae -- Medicinal plants classified in the family Rhizophoraceae -- Medicinal plants classified in the family Olacaceae -- Medicinal plants classified in the family Icacinaceae -- Medicinal plants classified in the family Euphorbiaceae -- Medicinal plants classified in the family Sapindaceae -- Medicinal plants classified in the family Anacardiaceae -- Medicinal plants classified in the family Simaroubaceae -- Medicinal plants classified in the family Meliaceae -- Medicinal plants classified in the family Rutaceae -- Medicinal plants classified in the family Loganiaceae -- Medicinal plants classified in the family Gentianaceae -- Medicinal plants classified in the family Apocynaceae -- Medicinal plants classified in the family Asclepiadaceae -- Medicinal plants classified in the family Solanaceae -- Medicinal plants classified in the family Verbenaceae.
- Medicinal plants of the world. v. 1-3 : chemical constituents, traditional and modern medicinal usesv. 3, 2005. Springerby Ivan A. Ross.Also available: Print – [v. 1], 1999Also available: Print – v. 2-3, 2001-2005.
- 2015 SpringerMira Harrison-Woolrych, editor.In this definitive new text, the major medicines, devices and vaccines used by women worldwide are brought together for the first time in a single volume. Written and edited by international experts with an evidence-based approach, Medicines for Women offers a comprehensive summary of all key areas. In the first part, issues relating to female drug exposure and prescribing to subgroups of women ℓ́ℓ for example during pregnancy and lactation, and to adolescent women ℓ́ℓ are presented in the context of contemporary clinical practice. In the second part, specific groups of medicines are reviewed, including oral contraceptives (with an additional chapter on venous thromboembolism), emergency contraception, contraceptive devices, treatment of chronic pelvic pain, hormone replacement therapy, bisphosphonates, herbal medicines for women, and human papilloma virus vaccines. Every chapter reviews and summarizes the efficacy and safety of each group of products and concludes with a useful set of clinical ℓ́ℓtake-homeℓ́ℓ messages. In the third part of the book, broader perspectives are presented ℓ́ℓ from a primary-care overview of prescribing for women, through to regulatory, political and religious aspects, including issues in developing countries. The two final chapters focus on communicating the benefits and risks of medicines for women. This book is aimed at prescribers, other healthcare professionals and students of womenℓ́ℓs health throughout the world. It is an extremely valuable resource for all in clinical practice, for students of medicine, nursing, pharmacy and related sciences, and also for those in medicines regulation, pharmacovigilance and the pharmaceutical industry.
- 2013 SpringerMichael A. Repka, Nigel Langley, James DiNunzio, editors.This inclusive text describes hot melt extrusion for pharmaceutical applications, focusing on the materials used for the preparation of solid dispersions, fundamentals for preparing such systems and novel applications using extrusion technology. Highlighting viewpoints from the academic, excipient, equipment, product development and regulatory communities, this comprehensive text compiles input from industry thought leaders to illustrate strategies and technologies for applying hot melt extrusion for drug product development while also providing insight into the path forward for the technology in years to come.
- 2003 Springer Protocolsedited by Qing Yan.Pharmacogenomics of membrane transporters an overview / Q. Yan -- The iubmb-endorsed transporter classification system / W. Busch and M.H. Saier, Jr. -- Bioinformatics and data integration in membrane transporter studies / Q. Yan -- DNA microarrays to analyze gene expression in animals with altered transporter expression / G.W. Miller -- Microarray data analysis in studies of membrane transporters / D. Hu -- Laser capture microdissection to examine transporter expression in specific cell regions / O. Rho and G.W. Miller -- Site-directed mutagenesis in the study of membrane transporters / R.M. Ryan, A.D. Mitrovic and R.J. Vandenberg -- Fluorescence techniques for studying membrane transport proteins: The p-glycoprotein multidrug transporter / F.J. Sharom [and others] -- Reconstitution of membrane transporters / F.J. Sharom and P.D. Eckford -- Equilibrium binding and transport studies / A.M. Ojeda [and others] -- Electrophysiological studies of ion channels and therapeutic potential with adenovirus-mediated gene transfer / J. Qu, T.V. Pham and M.N. Obreztchikova -- Antibody production and immunocytochemical localization of amino acid transporters / D.V. Pow, R. Sullivan and H. Scott -- Xenopus laevis oocytes / S. Broer -- Measurement of intracellular ph / F.B. Loiselle and J.R. Casey -- Small-angle x-ray scattering studies of membrane transporter peripheral components and soluble domains / B.H. Shilton -- Membrane protein nmr studies / S.J. Opella -- Analysis of soluble sugar permease domains by solution nmr / T.A. Wilkinson and Y. Chen -- Molecular modeling and molecular dynamics simulations of membrane transporter proteins / D.S. Dwyer -- Imaging plasma membrane proteins by confocal microscopy / S.W. Tsang and P.M. Haney.
- 2013 SpringerHenning Beck-Nielsen, editor.Metabolic syndrome is a common syndrome affecting about 20% of the adult population in Europe, and the prevalence is likely similar in other industrialised countries worldwide. It is mainly caused by the western lifestyle, which tends to produce abdominal obesity, but a genetic predisposition also plays a part. This syndrome, which is linked to leisure lifestyles and overeating/obesity, can develop into type 2 diabetes, cardiovascular disease and cancer. Therefore, proper treatment and prevention are essential. This book discusses lifestyle intervention and treatment, specifically with pharmacological compounds, in order to formulate a strategy for treating the metabolic syndrome in daily practice.
- 2012 Wileyedited by Pavel Anzenbacher and Ulrich M. Zanger.Biochemistry and molecular genetics of drug metabolism -- Drug-metabolizing enzymes: an overview -- Cytochromes P450 -- UDP-glucuronosyltransferases -- Sulfotransferases -- Glutathione s-transferases -- Hydrolytic enzymes -- Transporting systems -- Transcriptional regulation of human drug-metabolizing cytochrome P450 enzymes -- Importance of pharmacogenomics -- Metabolism of drugs -- Introduction to drug metabolism -- Central nervous system drugs -- Cardiovascular drugs -- Anticancer drugs -- Antimicrobial agents -- Drugs against acute and chronic pain -- Drugs of abuse (including designer drugs) -- Nicotine metabolism and its implications -- Metabolism of alcohol and its consequences -- Metabolism of natural compounds -- Introduction and overview -- Food components and supplements -- Metabolism of unnatural xenobiotics -- Environmental pollutants -- Environmental estrogens -- Biotransformation of insecticides.
- 2013 Springer Protocolsedited by Ute Roessner and Daniel Anthony Dias.Bryophytes: Liverworts, Mosses and Hornworts Extraction and Isolation Procedures -- Plant Tissue Extraction for Metabolomics -- Detection of Polar Metabolites through the use of Gas Chromatography Mass Spectrometry -- A Robust GC-MS Method for the Quantitation of Fatty Acids in Biological Systems -- A Workflow from Untargeted LC-MS Profiling to Targeted Natural Product Isolation -- Lipidomics Extraction Protocols for Biological Matrices -- Metabolite Analysis of Biological Fluids and Tissues by Proton Nuclear Magnetic Resonance Spectroscopy -- NMR Spectroscopy: Structure Elucidation of Cycloelatenene A: A Natural Product Case Study -- NMR-Based Metabolomics: A Probe to Utilize Biodiversity -- Extraction Protocol for Non-Targeted NMR and LC-MS Metabolomics-Based Analysis of Hard Coral and their Algal Symbionts -- Determination of Absolute Configuration Using Single Crystal X-ray Diffraction -- Natural Product Chemistry in Action: The Synthesis of Melatonin Metabolites K1 and K2 -- Discovery, Biosynthesis, and Rational Engineering of Novel Enterocin and Wailupemycin Polyketide Analogues -- Bioassays for Anticancer Activities -- Screening for Anti-Diabetic Activities -- Screening for Antibacterial, Antifungal and Anti-Quorum Sensing Activity -- Metabolomics and Dereplication Strategies in Natural Products -- Bridging the Gap: Basic Metabolomics Methods for Natural Product Chemistry -- Strategies in Biomarker Discovery. Peak Annotation by MS and Targeted LC-MS Micro-Fractionation for de novo Structure Identification by Micro-NMR -- Statistical Analysis of Metabolomics Data.
- 2005 Wiley[edited by] Marcel Gielen, Edward R.T. Tiekink.Chapter 1. ₃Li Lithium Metallotherapeutics / Robin S.B. Williams and Adrian J. Harwood, p. 1-17 -- Chapter 2. ₅B Boron Compounds as Therapeutic Drugs / Geeta Rana, Kamesh Vyakaranam, John A. Maguire and Narayan S. Hosmane, p. 19-49 -- Chapter 3. ₁₂Mg The Role of Magnesium As a Metallotherapeutic Drug / Pietro Delva, p. 51-64 -- Chapter 4. ₁₃Al Aluminum Metallotherapeutics / Thanos Salifoglou, p. 65-82 -- Chapter 5. ₁₄Si Biological Activity of Organosilicon Compounds / Edmunds Lukevics and Luba Ignatovich, p. 83-107 -- Chapter 6. ₂₀Ca The Role of Calcium As a Metallotherapeutic Drug / Mario Barbagallo and Ligia J. Dominguez, p. 109-124 -- Chapter 7. ₂₂Ti Anti-Tumor Titanium Drugs / Erich Dubler, p. 125-142 -- Chapter 8. ₂₃V Insulin-Mimetic Vanadium-Containing Compounds / Tamás Kiss and Tamás Jakusch, p. 143-158 -- Chapter 9. ₂₅Mn Manganese Metallotherapeutics / Jeanne H. Freeland-Graves, Tanushree Bose and Abbass Karbassian, p. 159-178 -- Chapter 10. ₂₆Fe The Use of Iron-Based Drugs in Medicine / Xiang Wu and Mei Lin Go, p. 179-200 -- Chapter 11. ₂₇Co Cobalt Complexes As Potential Pharmaceutical Agents / Hui Chao and Liang-Nian Ji, p. 201-218 -- Chapter 12. ₂₉Cu Chemotherapeutic Copper Compounds / Francisco González-Vílchez and Rosario Vilaplana, p. 219-236 -- Chapter 13. ₃₀Zn The Role of Zinc As a Metallotherapeutic Agent / Jane V. Higdon and Emily Ho, p. 237-257 -- Chapter 14. ₃₁Ga Therapeutic Gallium Compounds / Lawrence R. Bernstein, p. 259-277 -- Chapter 15. ₃₂Ge Biological Activity of Organogermanium Compounds / Edmunds Lukevics and Luba Ignatovich, p. 279-295 -- Chapter 16. ₃₃As Metallotherapeutic Arsenic Compounds / Paul C. Ho, p. 297-311 -- Chapter 17. ₃₄Se The Use of Selenium-Based Drugs in Medicine / Michael Carland and Tahli Fenner, p. 313-332 -- Chapter 18. ₄₃Tc Technetium in Medicine / Oyebola O. Sogbein and John F. Valliant, p. 333-358 -- Chapter 19. ₄₄Ru Perspectives of Ruthenium Complexes in Cancer Therapy / Olivier Lentzen, Cécile Moucheron and Andrée Kirsch-De Mesmaeker, p. 359-378 -- Chapter 20. ₄₅Rh Rhodium in Medicine / Florian P. Pruchnik, p. 379-397 -- Chapter 21. ₄₆Pd The Use of Palladium Complexes in Medicine / Achilleas Garoufis, Sotiris K. Hadjikakou and Nick Hadjiliadis, p. 399-419 -- Chapter 22. ₅₀Sn Tin Compounds and Their Therapeutic Potential / Marcel Gielen and Edward R.T. Tiekink, p. 421-439 -- Chapter 23. ₅₁Sb Antimony in Medicine / Siucheong Yan, Lan Jin and Hongzhe Sun, p. 441-461 -- Chapter 24. ₇₅Re Therapeutic Rhenium Radiopharmaceuticals / Jonathan R. Dilworth and Paul S. Donnelly, p. 463-487 -- Chapter 25. ₇₈Pt Platinum-Based Drugs / Viktor Brabec and Jana Kasparkova, p. 489-506 -- Chapter 26. ₇₉Au Gold-Based Metallotherapeutics: Use and Potential / Soo Yei Ho and Edward R.T. Tiekink, p. 507-527 -- Chapter 27. ₈₃Bi Bismuth-Based Pharmaceuticals / Neil Burford and Melanie D. Eelman, p. 529-540 -- Chapter 28. Paramagnetic Metal Complexes As Contrast Agents for Magnetic Resonance Imaging / Silvio Aime, Alessandro Barge, Eliana Gianolio, Simonetta Geninatti Crich, Walter Dastrú and Fulvio Uggeri, p. 541-560.
- 2012 SpringerSandra Ceccatelli, Michael Aschner, editors.Annotation Mercury (Hg) is a global pollutant that knows no environmental boundaries. Even the most stringent control of anthropogenic Hg sources will not eliminate exposure given its ubiquitous presence. Exposure to Hg occurs primarily via the food chain due to MeHgs accumulation in fish. Latest US statistics indicate that 46 States have fish consumption advisories. In addition, Hg is a common pollutant in hazardous waste sites, with an estimated 3-4 million children living within one mile of at least one of the 1,300+ active hazardous waste sites in the US. The effects on intellectual function in children prenatally exposed to MeHg via maternal fish consumption have been the subject of two on-going major, prospective, longitudinal studies in the Seychelles and the Faroe Islands. It is important to recognize that the risk for MeHg exposure is not limited only to islanders with high fish consumption. This bookwill provide state-of-the-art information to the graduate student training in toxicology, risk assessors, researchers and medical providers at large. It is aimed to bring the reader up to date on contemporary issues associated with exposure to methylmercury, from its effects on stem cells and neurons to population studies.
- 2011 SpringerBertil B. Fredholm, editor.Notes on the History of Caffeine Use / Bertil B. Fredholm -- Distribution, Biosynthesis and Catabolism of Methylxanthines in Plants / Hiroshi Ashihara, Misako Kato and Alan Crozier -- Pharmacokinetics and Metabolism of Natural Methylxanthines in Animal and Man / Maurice J. Arnaud -- Inhibition of Cyclic Nucleotide Phosphodiesterases by Methylxanthines and Related Compounds / Sharron H. Francis, Konjeti R. Sekhar, Hengming Ke and Jackie D. Corbin -- Methylxanthines and Ryanodine Receptor Channels / Serge Guerreiro, Marc Marien and Patrick P. Michel -- Xanthines as Adenosine Receptor Antagonists / Christa E. Müller and Kenneth A. Jacobson -- Theobromine and the Pharmacology of Cocoa / Hendrik Jan Smit -- Propentofylline: Glial Modulation, Neuroprotection, and Alleviation of Chronic Pain / Sarah Sweitzer and Joyce De Leo -- Methylxanthines, Seizures, and Excitotoxicity / Detlev Boison -- Impacts of Methylxanthines and Adenosine Receptors on Neurodegeneration: Human and Experimental Studies / Jiang-Fan Chen and Yijuang Chern -- Methylxanthines and Pain / Jana Sawynok -- Methylxanthines and Sleep / Tarja Porkka-Heiskanen -- Methylxanthines and Reproduction / Alba Minelli and Ilaria Bellezza -- Methylxanthines During Pregnancy and Early Postnatal Life / Ulrika Ådén -- Methylxanthines and the Kidney / Hartmut Osswald and Jürgen Schnermann -- The Cardiovascular Effects of Methylxanthines / Niels P. Riksen, Paul Smits and Gerard A. Rongen -- Methylxanthines in Asthma / Stephen L. Tilley -- Methylxanthines and Inflammatory Cells / György Haskó and Bruce Cronstein -- Methylxanthines, Inflammation, and Cancer: Fundamental Mechanisms / Akio Ohta and Michail Sitkovsky -- Methylxanthines and Drug Dependence: A Focus on Interactions with Substances of Abuse / Micaela Morelli and Nicola Simola -- Methylxanthines and Human Health: Epidemiological and Experimental Evidence / Marie-Soleil Beaudoin and Terry E. Graham.
- 2009 ClinicalKeyeditor, J.K. Aronson.Elsevier now offers a series of derivative works based on the acclaimed Meyler's Side Effect of Drugs, 15th Edition. These individual volumes are grouped by specialty to benefit the practicing physician and/or clinician. Many of the drugs currently available to physicians have a long history of use as herbal remedies, including opium, aspirin, digitalis, and quinine. This volume will be a reference to health professionals and homeopathic practitioners in understanding the effects of herbal drugs. Surpasses the Physician's Desk Reference © by including clinical case studies and independent exper.
- 2003 CRCnetBASE[edited by] Thomas J. Dougherty, Steven J. Projan.Also available: Print – 2003
- 2013 SpringerMarkus Müller, editor.In vivo target site concentrations are probably the most important determinant of drug effects. Traditionally, linking drug concentrations to drug effects has been accomplished by modelling blood-derived data, mostly because a direct quantification of tissue concentrations has been beyond technical reach. Today, a direct measurement of target site concentrations is possible by employing microdialysis or complementary approaches such as imaging technologies. Microdialysis, initially conceived in the 1970s, has become a standard tool in drug development. This comprehensive overview of current microdialysis technology covers general and disease-specific aspects of microdialysis by international experts in the field. It provides useful information for colleagues in academia and industry who are interested PK-PD aspects of drug development.
- 2012 WileyRyan F. Donnelly [and others].One of the latest techniques in drug delivery, microneedles are used for administering a wide range of drug substances used to treat various medical conditions. Thorough background information is included providing a history of the field. Various methods used to produce micorneedles are described as well as a snapshot of the future directions within the industry. Written by highly qualified authors, this new text is the only title providing a comprehensive review of microneedle research in the fields of transdermal and intradermal drug delivery.
- 2015 Springer Protocolsedited by Volkmar Weissig, Marvin Edeas.This expert volume covers an interdisciplinary and rapidly growing area of biomedical research comprising genetic, biochemical, pathological, and clinical studies aimed at the diagnosis and therapy of human diseases which are either caused by or associated with mitochondrial dysfunction. It dedicates itself to showcasing the tremendous efforts and the progress that has been made over the last decades in developing techniques and protocols for probing, imaging, and manipulating mitochondrial functions. "Mitochondrial Medicine: Volume II, Manipulating Mitochondrial Function" describes techniques developed for manipulating and assessing mitochondrial function under general pathological conditions and specific disease states. Written in the highly successful "Methods in Molecular Biology" series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls.Comprehensive and practical, "Mitochondrial Medicine" provides an essential source of know-how and inspiration to all researchers who are fascinated by this tiny organelle that seems so clearly to control the life and death of a single cell and whole organisms alike.
- 2008 SpringerJürgen Schüttler, Helmut Schwilden, editors ; contributors J. Ahonen ... [et al.].
- 2014 SpringerKeith A. Foster, editor.Currently, there are tremendous advances being made in understanding the basic science of both the structure and function of botulinum neurotoxins. This knowledge is opening up opportunities in regard to both therapeutic uses and treatment and protection options for civil and bio-defense applications. This volume fully evaluates the status of neurotoxin research and exploitation. The book is a multi-authored collection of chapters written by the leading authorities responsible for the current scientific and clinical research that is advancing the understanding and exploitation of the neurotoxins, and is both up to date and authoritative.
- 2006 Springereditor, Matthias Gaestel ; contributors, S. Alberti ... [et al.].
- 2010 Springeredited by Andreas Luch.
- 2012 Springeredited by Andreas Luch.Chemical Hazards in the Organisation / Chris Winder -- Toxicology of Water / Xiaowei Zhang, Steve Wiseman and John Giesy -- Perfluorinated Compounds / Christopher Lau -- Toxicologically Relevant Phthalates in Food / Oliver Kappenstein, Bärbel Vieth, Andreas Luch and Karla Pfaff -- Exposure to Polycyclic Aromatic Hydrocarbons: Bulky DNA Adducts and Cellular Responses / Frank Henkler, Kristin Stolpmann and Andreas Luch -- Heavy Metal Toxicity and the Environment / Paul B. Tchounwou, Clement G. Yedjou, Anita K. Patlolla and Dwayne J. Sutton -- Toxicology of Ambient Particulate Matter / Damiën van Berlo, Maja Hullmann and Roel P. F. Schins -- Nanomaterials: A Challenge for Toxicological Risk Assessment? / Andrea Haase, Jutta Tentschert and Andreas Luch -- Immunotoxicology and Its Application in Risk Assessment /; Andrew A. Rooney, Robert W. Luebke, MaryJane K. Selgrade and Dori R. Germolec.; Chemical Sensitization and Allergotoxicology / Rosette L. Van Den Heuvel, Nathalie Lambrechts, Sandra Verstraelen, Inge C. Nelissen and Greet E. R. Schoeters -- Male Reprotoxicity and Endocrine Disruption / Sarah Campion, Natasha Catlin, Nicholas Heger, Elizabeth V. McDonnell and Sara E. Pacheco, et al. -- Interspecies Uncertainty in Molecular Responses and Toxicity of Mixtures / Moiz M. Mumtaz and Hana R. Pohl -- Recent Trends in Statistical QSAR Modeling of Environmental Chemical Toxicity / Alexander Tropsha -- Chirality and Its Role in Environmental Toxicology / Imran Ali, Hassan Y. Aboul-Enein, Mohd Marsin Sanagi and Wan Aini Wan Ibrahim -- Genetic Variability in Molecular Responses to Chemical Exposure / Chirag J. Patel and Mark R. Cullen -- Biomarkers in Toxicology and Risk Assessment / Bruce A. Fowler -- A Personalized Life: Biomarker Monitoring from Cradle to Grave / Harald Jungnickel and Andreas Luch -- On the Role of Low-Dose Effects and Epigenetics in Toxicology / Lena Smirnova, Alexandra Sittka and Andreas Luch -- Hormesis: Improving Predictions in the Low-Dose Zone / E. J. Calabrese.
- 2009 Springeredited by Andreas Luch.
- 2012 CRCnetBASEedited by Beena Rai."Preface Over the past few decades, molecular modeling (MM) has become an important tool in many academic institutions and industrial laboratories. While the role of MM in biological fields--especially in the design and development of novel drug molecules or formulations--is well established and acknowledged, its direct role in the design and development of performance chemicals and novel materials is still not well known. Questions such as, which new products have resulted from an MM-based approach? are still often asked. Although MM may be playing an important role in product development, quite often it becomes difficult to predict its direct impact because most of the time the problem being addressed involves a multidisciplinary approach. Further, the assumption that fundamental phenomena being modeled though MM will have a direct impact on the macroscopic and functional properties of a product make the situation more complicated. In most of the cases, MM actually works as an enabler toward novel product and material development (e.g., novel drug molecules in biological application) rather than directly coming up with new products and materials. This precisely is the reason that despite seeing value in MM tools, most engineers and practitioners are often focus on the question, how do I leverage these tools to design and develop novel materials or chemicals for the industry I am working with? Unfortunately, there is no simple answer to this question. Excellent books and very good research publications highlight the most intricate, fundamental, and theoretical details about MM techniques and tools"-- Provided by publisher.
- 2013 SpringerLu-qi Huang, editor."This book reviews the latest developments in pharmacognosy, introduces a series of new views and insights, presents the hotspots and focus of the field of study on molecular pharmacognosy, and predicts a new direction of study on the resource science of TCM. Furthermore, the book also provides an open communications platform for the development of molecular pharmacognosy."--Publisher.
- 2013 SpringerMarie-Odile Parat, editor.This book would combine chapters written by the most qualified authors around the world whose research encompasses the effect of morphine or other opioids on tumor growth and metastasis. This includes clinicians involved in trials determining which type of post surgical pain management can minimize the risk of recurrence or metastasis, researchers working on animal models and studying the effect of morphine on tumors, and most importantly the mechanism for this effect, and lastly cell biologists. There is currently a lot of research going on trying to reconcile the pro- and anti-cancer aspects of opioids actions.
- 2014 Wileyedited by Vitaliy V. Khutoryanskiy.
- 2008 SpringerVladimir Torchilin, editor.
- 2012 SpringerAllison D. Fryer, Arthur Christopoulos, Neil M. Nathanson, editors.Muscarinic receptor pharmacology and signaling -- Overview of muscarinic receptor subtypes -- Structure-function studies of muscarinic acetylcholine receptors -- Polymorphisms in human muscarinic receptor subtype genes -- Muscarinic receptor trafficking -- Physiological role of G-protein coupled receptor phosphorylation -- Novel muscarinic receptor mutant mouse models -- Muscarinic receptors in the CNS -- Muscarinic receptor pharmacology and circuitry for the modulation of cognition -- Muscarinic agonists and antagonists in schizophrenia -- Muscarinic pain pharmacology: realizing the promise of novel anagesics by overcoming old challenges -- Muscarinic modulation of striatal function and circuitry -- Muscarinic receptors in brain stem and mesopontine cholinergic arousal functions -- Muscarinic receptors in autonomic effector organs -- Muscarinic receptor agonists and antagonists: effects on ocular function -- Muscarinic receptor agonists and antagonists: effects on cardiovascular function -- Muscarinic receptor antagonists: effects on pulmonary function -- Muscarinic agonists and antagonists: effects on gastrointestinal function -- Muscarinic agonists and antagonists: effets on the urinary bladder -- Muscarinic receptors and mediation of hormonal effects of acetylcholine -- Muscarinic receptor agonists and antagonists: effects on inflammation and immunity -- Muscarinic receptor agonists and antagonists: effects on keratinocyte functions -- Muscarinic receptor agonists and antagonists: effects on cancer -- Activation of muscarinic receptors by non-neuronal acetylcholine.
- 2013 Wileyedited by Ashutosh Tiwari and Atul Tiwari."Nanoscopic therapeutic systems incorporate therapeutic agents, molecular targeting and diagnostic imaging capabilities and are emerging as the next generation of multifarious nanomedicine to improve the therapeutic outcome including chemo and translational therapy. This reference work is one of the first to cover Nanotheragnostics which is the new edge of nanomedicine combining both diagnostic and therapeutic elements at nano level. This large multidisciplinary reference work is has four main parts: Biocompatible Nanomaterials; Nanomedicine: Drug Gene and Cell Delivery; Multi-functional Nanocarrier: Diagnosis, Imaging and Treatment; Tissue Engineering/Regenerative Medicine"-- Provided by publisher.
- 2009 ScienceDirectedited by Hari S. Sharma.
- 2015 CRCnetBASE[edited by] Jose L. Arias."Pharmacotherapy is often limited by the inefficient activity and severe toxicity of drug molecules. Nanotechnology offers a revolutionary and definitive approach for the efficient delivery of drug molecules to non-healthy tissues and cells. This first volume of a series of two volumes analyzes the basics in the development of drug-loaded nanoplatforms, the so-called nanomedicines. Special attention is given to physicochemical engineering, pharmacokinetics, biocompatibility and biodegradability, representative nanoplatforms (based on lipids, polymers, cyclodextrins, metals, carbon, silica, iron oxides, etc.), and advanced nano-engineering strategies for passive, ligand-mediated, and/or stimuli-sensitive drug delivery and release"--Provided by publisher.
- 2009 Springer[edited by] Melgardt M. de Villiers, Pornanong Aramwit, Glen S. Kwon.
- v.1-2=, 2008 SpringerVol. II (2008) Springeredited by Frank Petersen and René Amstutz.
- 2005 Springeredited by Lixin Zhang, Arnold L. Demain.Natural products and drug discovery / Arnold L. Demain and Lixin Zhang -- Integrated approaches for discovering novel drugs from microbial natural products / Lixin Zhang -- Automated analyses of HPLC profiles of microbial extracts: a new tool for drug discovery screening / Jose R. Tormo and Juan B. Garcia -- Manipulating microbial metabolites for drug discovery and production / C. Richard Hutchinson -- Improving drug discovery from microorganisms / Chris M. Farnet and Emmanuel Zazopoulos -- Developments in strain improvement technology: evolutionary engineering of industrial microorganisms through gene, pathway, and genome shuffling / Stephen B. del Cardayr -- The discovery of anticancer drugs from natural sources / David J. Newman and Gordon M. Cragg -- Case studies in natural product optimization: novel antitumor agents derived from Taxus brevifolia and Catharanthus roseus / Jian Hong and Shu-Hui Chen -- Terpenoids as therapeutic drugs and pharmaceutical agents / Guangyi Wang, Weiping Tang and Robert R. Bidigare -- Challenges and opportunities in the Chinese herbal drug industry / Wei Jia and Lixin Zhang -- Arsenic trioxide and leukemia: from bedside to bench / Guo-Qiang Chen ... [et al.] -- New methods to access microbial diversity for small molecule discovery / Karsten Zengler, Ashish Paradkar, and Martin Keller -- Accessing the genomes of uncultivated microbes for novel natural products / Asuncion Martinez ... [et al.] -- New natural product diversity from marine actinomycetes / Paul R. Jensen and William Fenical -- Novel natural products from rainforest endophytes / Gary Strobel, Bryn Daisy, and Uvidelio Castillo -- Biological, economic, ecological, and legal aspects of harvesting traditional medicine in Ecuador / Alexandra Guevara-Aguirre and Ximena Chiriboga.
- 2013 SpringerFrank E. Koehn, editor.Part 1. Natural Product Drugs and Cancer Therapeutics -- The Impact of Natural Products Upon Cancer Chemotherapy / A. Ganesan -- Identification and Development of Vascular Disrupting Agents: Natural Products That Interfere with Tumor Growth / Andrea T. Hooper, Frank Loganzo, Chad May and Hans-Peter Gerber -- Discodermolide: Past, Present, and Future / Ross E. Longley -- HDAC Inhibitors and Other Histone Modifying Natural Products as Emerging Anticancer Agents / Lilibeth A. Salvador and Hendrik Luesch -- Natural Product Cytotoxins as Payloads for Antibody Drug Conjugates / Frank E. Koehn -- Part 2. Advances in Natural Product Cancer Drug Discovery -- Natural Product Scaffolds in Cancer Therapy / Christian P. Mang and Lars Ole Haustedt -- The Role of Genetic Engineering in Natural Product-Based Anticancer Drug Discovery / Claudia Eva-Maria Unsin, Scott R. Rajski and Ben Shen -- Accessing Anti-cancer Natural Products by Plant Cell Culture / Lisa M. Leone and Susan C. Roberts -- Natural Products as Tools for Discovering New Cancer Targets / John A. Beutler.
- 2012 Springer Protocolsedited by Satyajit D. Sarker, Lutfun Nahar.An introduction to natural products isolation -- Initial and bulk extraction of natural products isolation -- Supercritical fluid extraction in natural products analyses -- Accelerated solvent extraction for natural products isolation -- Microwave-assisted extraction in natural products isolation -- An introduction to planar chromatography and its application to natural products isolation -- Isolation of natural products by low-pressure column chromatography -- Isolation of natural products by ion-exchange methods -- Separation of natural products by countercurrent chromatography -- Isolation of natural products by preparative high performance liquid chromatography (prep-HPLC) -- Isolation of natural products by preparative gas chromatography -- Hyphenated techniques and their applications in natural products analysis -- Extraction of plant secondary metabolites -- Isolation of marine natural products -- Isolation of microbial natural products -- Extraction and isolation of saponins -- Extraction and isolation of phenolic compounds -- Scaling-up of natural products isolation -- Follow-up of natural products isolation -- Natural products isolation in modern drug discovery programs.
- 2014 ClinicalKeyRobert B. Raffa, Scott M. Rawls, Elena Portyansky Beyzarov ; illustrations by Frank H. Netter.This updated edition of Netter's Illustrated Pharmacology allows you to take a distinct visual approach to understanding both the basic science and clinical applications of pharmacology. Designed to be compatible and used in conjunction with other pharmacology resources, this medical reference book offers a vivid, uniquely effective visual presentation of the pharmacodynamic relationship between drugs and the human body. And with the new addition of Student Consult online access, Netter's Illustrated Pharmacology is even more convenient than ever before! Available online for the first time! Search the full contents of Netter's Illustrated Pharmacology no matter what your location with convenient access to Student Consult.Visually grasp the most important principles in pharmacology with succinct, easy-to-understand presentations of introductory pharmacologic principles based on classic images by Frank Netter, as well as dynamic new illustrations from other talented medical artists.Learn how drugs are used to treat specific disorders in the body, as well as their effects on a particular site, with a format divided by organ system and full-color illustrations of the systems themselves.Access in-depth guidance on the must-know elements of each pharmacologic principle with clear, concise notes located beneath the corresponding image.
- 2015 SpringerDaniel Thomas Ginat, Juan E. Small, Pamela Whitney Schaefer, editors.This book reviews the imaging features associated with selected classes of pharmaceuticals and drugs on brain, head and neck, and spine and explains the implications of the imaging findings for the neuroradiologist and the clinician. Some agents produce characteristic abnormalities with distinctive imaging features, while others have a spectrum of manifestations on imaging. Still further agents produce rather nonspecific changes on imaging, requiring a differential diagnosis. In this book, informative cases are depicted by rich images, with concise accompanying explanatory text that reviews the class of agent and the mechanism of action and discusses image interpretation and its significance.
- 2015 SpringerDavid J.K. Balfour, Marcus R. Munafó, editors.Imaging Tobacco Smoking with PET and SPECT -- Behavioral Mechanisms Underlying Nicotine Reinforcement -- The Role of Mesoaccumbens Dopamine in Nicotine Dependence -- Nicotine Withdrawal -- Neurobiologal bases of cue- and nicotine-induced reinstatement of nicotine seeking -- Psychiatric disorders as vulnerability factors for nicotine addiction: What have we learned from animal models?.
- 2006 Springercontributors, G. Ahnert-Hilger ... [et al.] ; editors, Harald H. Sitte and Michael Freissmuth.
- 2014 Springeredited by Gary R. Lewin, Bruce D. Carter.This book provides critical reviews of the role of neurotrophins and their receptors in a wide variety of diseases including neurodegenerative diseases like Huntington's syndrome, cognitive function, psychiatric disorders such as clinical depression, Rett syndrome, motoneurone disease, spinal cord injury, pain, metabolic disease and cardiovascular disease. It also contains contributions from leaders in the field dealing with the basic biology, transcriptional and post-translational regulation of the neurotrophins and their receptors. The present book will review all recent areas of progress in the study of neurotrophins and their biological roles.
- 2016 SpringerUlrich Nielsch, Ulrike Fuhrmann, Stefan Jaroch, editors.This volume gives an overview of state of the art technologies and future developments in the field of preclinical pharmaceutical research. A balanced mix of experts from academia and industry give insight in selected new developments in the drug discovery pathway. The topics cover the different parts of the drug discovery process, starting with new developments in the target identification and validation area. The lead generation part as a next step focuses on the requirements and technologies to identify new small molecules as lead compounds for further optimization; in a second section the technologies to identify biologics as leads are addressed. The final part focuses on the pharmacological models and technologies to characterize new compounds and the impact of biomarkers to facilitate the transfer of drug candidates into the development phase.
- 2015 SpringerSoodabeh Saeidnia.This book provides an up-to-date review of recently identified natural anti-tumor compounds from various natural origins including plants, fungi, endophytic fungi and marine organisms. It also℗ℓincludes discussion of℗ℓnew areas℗ℓsuch as℗ℓbiotechnology and nanoparticles. Chapters explain the challenges and developments in anti-cancer drug discovery approaches, traditional remedies for prevention and treatment of cancer, marine-derived anti-cancer compounds, and antibiotics used as anti-cancer agents, as well as different classes of terpenoids and carbohydrates, which have℗ℓbeen the subject of discussion℗ℓin this field as efficient anti-cancer candidates. This book will be a concise guide for researchers in the field of pharmaceutical sciences, students and residents in pharmacy and medicine as well as those researching phytochemistry and natural products.
- 2010 SpringerJ. Rick Turner.New drug development -- The regulatory environment -- Drug discovery -- Nonclinical research -- Designing clinical trials -- Conducting clinical trials I: Experimental methodology -- Conducting clinical trials II: Operational execution -- Statistical analysis -- Statistical significance -- Clinical significance -- Sample size estimation -- General safety assessments -- Efficacy assessment -- Cardiac and cardiovascular safety assessments -- Manufacturing small molecule drugs and biologicals -- Postmarketing surveillance -- Main themes and concluding comments -- References -- Index.
- 2009 SpringerJack E. Henningfield, Edythe D. London, Sakire Pöğün, editors ; contributors, D.L. Ashley ... [et al.].Global patterns of nicotine and tobacco consumption / S.K. Hammond -- Nicotine chemistry, metabolism, kinetics and biomarkers / N.L. Benowitz, J. Hukkanen and P. Jacob, 3rd -- Nicotine content and delivery across tobacco products / M.V. Djordjevic and K.A. Doran -- The road to discovery of neuronal nicotinic cholinergic receptor subtypes / A.C. Collins ... [et al.] -- Magnetic resonance imaging studies of cigarette smoking / A. Azizian ... [et al.] -- In vivo brain imaging of human exposure to nicotine and tobacco / A. Sharma and A.L. Brody -- Molecular and cellular mechanisms of action of nicotine in the CNS / J. Barik and S. Wonnacott -- The neuronal pathways mediating the behavioral and addictive properties of nicotine / D.J. Balfour -- Molecular genetics of nicotine metabolism / J.C. Mwenifumbo and R.F. Tyndale -- Sex differences in nicotine action / S. Pogun and G. Yararbas -- Recognising nicotine: the neurobiological basis of nicotine discrimination / J.W. Smith and I.P. Stolerman -- Effects of nicotine in experimental animals and humans: an update on addictive properties / B. Le Foll and S.R. Goldberg -- Discriminative stimulus effects of nicotine in humans / K.A. Perkins -- Rodent models of nicotine withdrawal syndrome / D.H. Malin and P. Goyarzu -- Approaches, challenges, and experience in assessing free nicotine / D.L. Ashley ... [et al.] -- Tobacco industry manipulation of nicotine dosing / G.F. Wayne and C.M. Carpenter -- Pharmacotherapy for tobacco dependence / R.V. Fant ... [et al.] -- Nicotine psychopharmacology: policy and regulatory / J.E. Henningfield and M. Zeller.
- 2005 Springeredited by K.D. Rainsford.
- Nitric oxide. Part D, Nitric oxide detection, mitochondria and cell functions, and peroxynitrite reactions2002 ScienceDirectedited by Enrique Cadenas, Lester Packer.Also available: Print – 2002
- 2011 SpringerNathan S. Bryan, Joseph Loscalzo, editors.
- 2015 SpringerDaan J.A. Crommelin, Jon S.B. de Vlieger, editors.Introduction: defining the position of non-biological complex drugs -- Polymeric micelles -- Liposomes: the science and the regulatory landscape -- Glatiramoids -- Iron carbohydrate complexes: characteristics and regulatory challenges -- Drug nanocrystals -- Analytical methods for determining the size (distribution) in parenteral dispersions -- NBCD pharmacokinetics and bioanalytical methods to meaure drug release -- Low molecular weight heparins, biological drugs close to non-biological complex drugs -- Nanoparticle albumin-bound anticancer agents -- The EU regulatory landscape of non-biological complex drugs -- Epilogue: What did we learn? What can we expect in the future? Concluding remarks and outstanding issues -- Index.
- 2013 ScienceDirectedited by Lisa Plitnick, Danuta Herzyk.Machine generated contents note: I.Development of Biophar-Maceuticals Defined as Novel Biologics -- 1.Overview of Biopharmaceuticals and Comparison with Small-molecule Drug Development / Thomas R. Gelzleichter -- Introduction -- History and Evolution of Biopharmaceuticals -- Development of Diverse Biopharmaceutical Modalities -- Comparison of Small-Molecule Drugs to Biopharmaceuticals -- Summary -- References -- 2.Regulatory Guidelines and their Application in the Nonclinical Evaluation of Biological Medicines / Maggie Dempster -- Introduction -- Species Selection -- Study Design Considerations for Repeat-Dose Studies -- Immunogenicity -- Reproductive and Developmental Toxicity -- Genotoxicity and Carcinogenicity -- Special Considerations for Anticancer Drugs -- First-in-Human (Fih) Clinical Trial -- Summary -- References -- 3.Early De-risking Strategy for Novel Biotherapeutics / Beth Hinkle -- Introduction -- Establishing A Safety Profile for Biotherapeutics -- General Safety Considerations Related to Biotherapeutics -- Progress in Evaluation of Immunotoxicity -- Can We Better Address Potential Off-Target Toxicity? -- Summary -- References -- 4.Novel Biopharmaceuticals: Pharmacokinetics, Pharmacodynamics, and Bioanalytics / Wolfgang Seghezzi -- Introduction -- Absorption, Distribution and Elimination of Biopharmaceuticals -- Disposition of Modified Molecules -- "Metabolism" and Biodistribution for Biopharmaceuticals -- Immunogenicity and impacts on PK and biodistribution -- Pharmacokinetics and Pharmacodynamics -- Preclinical to Clinical Translation -- Bioanalytics -- Drug Assays -- Biomarkers: Target Engagement Assays -- Immunogenicity Assessment: ADA Assays -- Summary -- References -- II.Development of Biosimilars -- 5.Overview of Biosimilar Therapeutics / Danuta J. Herzyk -- Introduction -- The Concept of Biosimilars -- General Considerations for Development of Biosimilars -- Biosimilar Candidates Based on Modality and Therapeutic Class -- Summary -- References -- 6.Regulatory Standards for the Approval of Biosimilar Products: A Global Review / Barbara Mounho-Zamora -- Introduction -- European Union -- Pioneer for the First Regulatory Pathway for Biosimilar Products -- The World Health Organization Guidance on Biosimilars -- Regulatory Pathway for Biosimilar Products in the United States -- Biosimilar Pathways in Other Regions -- Summary -- References -- 7.Early Characterization of Biosimilar Therapeutics / Thomas R. Gelzleichter -- Introduction -- Recombinant Insulins -- Recombinant Human Growth Hormone -- Recombinant Erythropoietins -- Recombinant Granulocyte Colony-Stimulating Factor -- Recombinant Interferons -- Low Molecular Weight Heparins -- Monoclonal Antibodies -- Other Classes -- Summary -- References -- III.Vaccines -- 8.Introduction to Vaccines and Adjuvants / Deborah L. Novicki -- Introduction -- The History of Vaccines -- The Impact of Vaccines on Human Health -- Advancements in Vaccines Technologies -- Advancements in Adjuvant Technologies -- Approved Infectious Disease Vaccines and Diseases for Which Preventive Vaccines are Still Needed -- Therapeutic Vaccines -- Product Complexity From a Quality Perspective -- Nonclinical Testing -- Clinical Testing -- Vaccine Development Using the Animal Rule -- The Anti-Vaccines Movement and Misperceptions About Vaccines and Their Safety -- Summary -- References -- 9.Global Regulatory Guidelines for Vaccines / Lisa M. Plitnick -- Introduction -- Toxicity Assessment -- Additional Toxicity Assessments -- Special Considerations -- Formulation/Delivery Devices -- Alternate Routes of Administration -- Special Considerations for Particular Types of Vaccines -- Summary -- References -- 10.Special Considerations for the Nonclinical Safety Assessment of Vaccines / Jayanthi J. Wolf -- Introduction -- De-risking Strategies for Vaccines -- Pharmacokinetics and Pharmacodynamics Assessments -- Differences in the Nonclinical Safety Assessment of Vaccines and Biopharmaceutical Drugs -- Summary -- References -- IV.Specialty Biologics and Indications -- 11.Turning the Corner with Viral-based Gene Therapy -- Development of the Rogue Biopharmaceutical / Timothy K. Maclachlan -- Introduction -- A History and Primer of Gene Therapy -- The Process of Getting Genes into Cells -- Health Authority Regulation of Gene Therapy Products -- Nonclinical Safety Studies and Regulatory Guidance -- Summary -- References -- 12.Blood Products / Vikram Arora -- Introduction -- Plasma-Derived Blood Products -- Blood Products Derived from Recombinant Technologies -- Summary -- References -- 13.Biological Therapies for Cancer / Gautham K. Rao -- Introduction -- Global Regulatory Guidances -- General Principles of Toxicology Assessments -- Nonclinical Studies and Principles of Study Design -- Specialty Toxicology Assessments -- Pharmacokinetics, Immunogenicity, and Pharmacodynamics -- Nonclinical Development of Marketed Biologies -- Recombinant Analogs of Endogeneous Human Proteins (Interferons, Cytokines, Enzymes) -- Summary -- References -- 14.Nonclinical Development of Multi-targeting Biopharmaceuticals / Anu V. Connor -- Introduction -- Scientific Rationale for Multi-Targeting Biopharmaceuticals (MTBs) -- Evolution of Technology Platforms -- General Challenges and Considerations -- Summary of Challenges -- T Cell-Dependent Bispecific Antibody (TDB) Biotherapeutics -- Dual-Targeting Antibodies -- Summary -- References -- 15.Considerations in the Development of Pluripotent Stem Cell-based Therapies / Joy A. Cavagnaro -- Introduction -- Early Decisions -- Nonclinical Development -- Translating Preclinical Data to Clinical Application -- Global Regulatory Guidance -- Summary -- References.
- 2013 Wileyedited by William J. Brock, Kenneth L. Hastings, and Kathy McGown.Introduction to the development of drugs / Kathy McGown -- ICH / Ken Hastings -- USFDA / Bill Brock -- Latin America : MERCOSUR countries / Cristiana Leslie Corra -- Canada / Mark T. Goldberg -- EMEA / Adam Woolley -- Africa / Fariza Feraoun -- China / Lijie Fu -- Japan / Kazuichi Nakamura -- India / K.S. Rao -- Australia / Doug Francis -- Chronic repeat dose testing / Shana Azri-Meehan -- Carcinogenicity / James Popp -- Genotoxicity / Mark Powley -- Developmental and reproductive toxicology / Robert Parker -- Juvenile testing and pediatric claim / Melissa Tassinari -- Immunotoxicology / Leigh Ann Burns Naas -- Biologics / Chris Ellis -- Vaccines / Robert House -- Phototoxicity and photocarcinogenicity / Chris Sambuco -- Degradants, impurities excipients, and metabolites / Bob Osterberg.
- 2016 SpringerEduard Shantsila, Gregory YH Lip.1. Introduction -- 2. Direct thrombin inhibitors -- 3. Factor Xa inhibitors -- 4. Conclusions.
- 2006 ScienceDirecteditors Alex A. Adjei, John K. Buolamwini.A survey of novel molecular targets for anticancer drug discovery -- Microarrays: small spots produce major advances in pharmacogenomics -- Strategies to target chemotherapeutics to tumors -- QSAR and pharmacophore mapping strategies in novel anticancer drug discovery -- Applications of nuclear magnetic resonance and mass spectrometry to anticancer drug discovery -- Antisense strategies for the development of novel cancer therapeutics -- Antibodies and vaccines as novel cancer therapeutics -- Inhibitors as targets for cancer therapy -- Preclinical testing and validation of novel anticancer agents -- Surrogate end points and biomarkers for early trials of novel anticancer agents -- Regulatory considerations in clinical trials of novel anticancer drugs -- Improving the efficacy and safety of anticancer agents: the role of pharmacogenetics -- Imaging of pharmacodynamic end points in clinical trials -- Devising proof-of-concept strategies in oncology clinical trials -- Clinical trial designs for cytostatic agents and agents directed at novel molecular targets -- Cancer gene therapy clinical trials: from the bench to the clinic -- Molecular targets for radiosensitization -- Patient accrual to clinical trials.
- 2012 SpringerMark A. Geyer, Gerhard Gross, editors.This volume tries to put current therapy - achievements, shortcomings, remaining medical needs - and emerging new targets into the context of increasing knowledge regarding the genetic and neurodevelopmental contributions to the pathophysiology of schizophrenia. Some of the chapters also deal with respective experimental and clinical methodology, biomarkers, and translational aspects of drug development. The volume concentrates on reviewing the ongoing research attempting to identify novel treatments for the cognitive deficits and negative symptoms of schizophrenia, which are not treated adequately by current antipsychotic medications.
- 2015 SpringerK.D. Rainsford, M.C. Powanda, M.W. Whitehouse, editors.Aloe vera: a Natural Healing Agent for Gastro-intestinal and Chronic Inflammatory Conditions -- Chondroitin Sulphate and Glucosamine Sulphate as Potential Disease-Modifying Agents for Osteoarthritis -- Probiotics as Natural Healing Agents for Gastro-intestinal Diseases and Arthritis.- Therapeutic Effects of Ribonucleinate (Ribonucleotides) in Immuno-inflammatory and Arthritic Diseases -- The Medicinal Properties and Phytochemistry of Plants of the Genus Terminalia (Combretaceae) -- Celery Seed and Related Extracts with Anti-athritic, Anti-Ulcer and anti-Microbial Activities -- Lyprinol, Lipids and other Components of Green Lipped Mussel as Anti-Arthritic and Anti-Ulcer Agents -- Zinc Compounds as Topical and Oral Anti-Arthritic and Anti-ulcer Compounds.
- 2014 SpringerRakesh Kumar, editor.Preface -- Steroid Receptor Coactivators (SRCs) as Integrators of Multiple Signaling Pathways in Cancer Progression -- Role of Alteration/Deficiency in Activation (ADA) Complex in the Cell Cycle, Genomic Instability and Cancer -- RUNX2 Transcriptional Regulation in Development and Disease -- Epigenetic Mechanisms of Cancer Metastasis -- Regulatory Effects of Arsenic on Cellular Signaling Pathways: Biological Effects and Therapeutic Implications -- Nuclear Factors Linking Cancer and Inflammation -- Regulation of the Jak/STATs Pathways by Histone Deacetylases -- Receptor Tyrosine Kinases in the Nucleus: Nuclear Functions and Therapeutic Implications in Cancers -- Nucleolar Signaling Determines Cell Fate The RP-Mdm2-p53 Axis Fine-Tunes Cellular Homeostasis -- Transcriptional Regulation of Lipogenesis as a Therapeutic Target for Cancer Treatment -- Selective Inhibition of Acetyl-Lysine Effector Domains of the Bromodomain Family in Oncology -- Domain Specific Targeting of Cancer -- The Potential of Targeting Splicing for Cancer Therapy -- Exploiting Cell Cycle Pathways in Cancer Therapy: New (and Old) Targets and Potential Strategies -- Histone Demethylases in Prostate Cancer -- Therapeutic Significance of Chromatin Remodeling Complexes in Cancer -- Index.
- 2014 Springer Protocolsedited by Brian C. Gilger.Challenges in ocular pharmacokinetics, pharmacodynamics, and toxicology / Brian C. Gilger -- Selection of appropriate animal models in ocular research : ocular anatomy and physiology of common animal models / Brian C. Gilger, Eva Abarca, and Jacklyn H. Salmon -- Challenges and strategies in drug residue measurement (bioanalysis) of ocular tissues / Poonam R. Velagaleti and Michael H. Buonarati -- Chemistry, manufacturing, and control of ophthalmic formulations / Malay Ghosh and Imran Ahmed -- ADME and ocular therapeutics : retina / Cornelis J. Van der Schyf, Samuel D. Crish, Christine Crish, Denise Inman, and Werner J. Geldenhuys -- Compositions, formulation, pharmacology, pharmacokinetics, and toxicity of topical, periocular, and intravitreal ophthalmic drugs / Kishore Cholkar, Aswani Dutt Vadlapudi, Hoang M. Trinh, and Ashim K. Mitra -- Sustained-release ocular drug delivery systems : bench to bedside development / Susan S. Lee, Michael R. Robinson, and Scott M. Whitcup -- Ophthalmic examination as it pertains to general ocular toxicology : basic and advanced techniques and species-associated findings / David A. Wilkie -- Study design and methodologies for evaluation of anti-glaucoma drugs / Paul E. Miller -- Study design and methodologies for study of ocular medical devices / Joseph W. Carraway and Elaine M. Daniel -- Methodologies for microscopic characterization of ocular toxicity / Leandro B.C. Teixeira and James A. Render -- Nanoparticles for drug and gene delivery in treating diseases of the eye / Shreya S. Kulkarni and Uday B. Kompella.
- 2009 SpringerReginald L. Dean III, Edward J. Bilsky, S. Stevens Negus, editors.
- 2011 SpringerGavril W. Pasternak, editor.
- 2015 Springer Protocolsedited by Santi M. Spampinato.Overview of genetic analysis of human opioid receptors / Santi M. Spampinato -- Computational structural biology of opioid receptors / Davide Provasi -- Analysis of epigenetic mechanisms regulating opioid receptor gene transcription / Cheol Kyu Hwang [and three others] -- Renilla luciferase reporter assay to study 3'UTR-Driven posttranscriptional regulations of OPRM1 / Gabriele Vincelli and Andrea Bedini -- High-throughput gene expression profiling of opioid-induced alterations in discrete brain areas / Michal Korostynski [and three others] -- Real-time imaging of mu opioid receptors by total internal reflection fluorescence microscopy / Cristina Roman-Vendrell and Guillermo Ariel Yudowski -- In vivo techniques to investigate the internalization profile of opioid receptors / Amynah A. Pradhan [and three others] -- Monitoring opioid receptor dimerization in living cells by bioluminescence resonance energy transfer (BRET) / Monica Baiula -- Analysis of potassium and calcium imaging to assay the function of opioid receptors / Viola Spahn, Dinah Nockemann, and Halina Machelska -- Electrophysiological patch clamp assay to monitor the action of opioid receptors / Viola Spahn, Dinah Nockemann, and Halina Machelska -- Skin-nerve preparation to assay the function of opioid receptors in peripheral endings of sensory neurons / Rabih Moshourab, Yvonne Schmidt, and Halina Machelska -- Mechanical nociception measurement in mice and rats with automated Von Frey equipment / Gabriele Campana and Roberto Rimondini -- Detecting zinc release induced by mu-opioid receptor agonists in brain slices / María Rodríguez-Muñoz [and three others] -- Opioid receptors : methods for detection and their modes of actions in the eye / Shahid Husain -- Evaluation of murine macrophage cytokine production after in vivo morphine treatment / Silvia Franchi [and four others] -- Measurement of macrophage toll-like receptor 4 expression after morphine treatment / Mara Castelli [and three others] -- The role of opioid receptors in migration and wound recovery in vitro in cultured human keratinocytes and fibroblasts / Mei Bigliardi-Qi and Paul L. Bigliardi -- Role of opioid receptors in the reinstatement of opioid- seeking behavior : an overview / Liana Fattore [and three others] -- Analysis of opioid-seeking reinstatement in the rat / Liana Fattore [and three others] -- Induction of a high alcohol consumption in rats and mice : role of opioid receptors / Roberto Rimondini and Gabriele Campana -- Evaluation of social and nonsocial behaviors mediated by opioids in mouse pups / Francesca R. D'Amato.
- 2007 SpringerDouglas J. Rhee ... [et al.]1 Antibacterial agents -- 2 Antifungal agents -- 3 Antiviral agents -- 4 Antiparasitic agents -- 5 Antiglaucoma agents -- 6 Neuro-ophthalmology -- 7 Anti-inflammatory agents -- 8 Mydriates, cycloplegics, and reversal agents -- 9 Lubricants and viscoelastics -- 10 Miscellaneous conditions -- 11 Anti-angiogenesis agents -- 12 Contact lens.
- 2014 Springer Protocolsedited by Gary W. Caldwell and Zhengyin Yan, CREATe Analytical Sciences, Janssen Research & Development, LLS, Spring House, PA, USA.Thoroughly revised and updated, Optimization in Drug Discovery: In Vitro Methods, Second Edition presents a wide spectrum of in vitro assays including formulation, plasma binding, absorption and permeability, cytochrome P450 (CYP) and UDP-glucuronosyltransferases (UGT) metabolism, CYP inhibition and induction, drug transporters, drug-drug interactions via assessment of reactive metabolites, genotoxicity, and chemical and photo-mutagenicity assays. Written for the Methods in Pharmacology and Toxicology series, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible protocols, and tips on troubleshooting and avoiding known pitfalls. Expert authors have developed and utilized these in vitro assays to achieve drug-like characteristics in addition to efficacy properties and good safety profiles of drug candidates. Comprehensive and up-to-date, Optimization in Drug Discovery: In Vitro Methods, Second Edition aims to guide researchers down the difficult path to successful drug discovery and development.
- 2006 SpringerRonald T. Borchardt ... [et al.], editors.
- 2015 SpringerStuart MacLeod, Suzanne Hill, Gideon Koren, Anders Rane, editors.
- 2009 SpringerAndreas Bernkop-Schnürch, editor.
- 2012 SpringerStephen T Sonis.Treatment tolerance is a challenge for most cancer patients, and it is therefore essential that healthcare professionals (HCP) are quick to recognize adverse events and implement management strategies to address them. This pocket book provides an in-depth guide to the epidemiology, diagnosis and management of oral mucositis, a common adverse event of chemotherapy.
- 2015 SpringerHans-Georg Schaible, editor.Emerging concepts of pain therapy based on neuronal mechanisms -- The pharmacology of nociceptor priming -- Sodium channels and pain -- Role of nerve growth factor in pain -- Central sensitization in humans: assessment and pharmacology -- Nitric oxide-mediated pain processing in the spinal cord -- The role of the endocannabinoid system in pain -- The role of glia in the spinal cord in neuropathic and inflammatory pain -- Plasticity of inhibition in the spinal cord -- Modulation of peripheral inflammation by the spinal cord -- The relationship between opiods and immune signalling in the spinal cord -- The role of proteases in pain -- Amygdala pain mechanisms -- Itch and pain differences and commonalities -- Index.
- 2012 SpringerKlaus Aktories, Joachim H.C. Orth, Ben Adler, editors.Pasteurella multocida: Diseases and Pathogenesis / I. W. Wilkie, M. Harper, J. D. Boyce and B. Adler -- Pathogenomics of Pasteurella multocida / J. D. Boyce, T. Seemann, B. Adler and M. Harper -- The Key Surface Components of Pasteurella multocida: Capsule and Lipopolysaccharide / Marina Harper, John D. Boyce and Ben Adler -- Pasteurella multocida and Immune Cells / Katharina F. Kubatzky -- Molecular Biology of Pasteurella multocida Toxin / Joachim H. C. Orth and Klaus Aktories -- Pasteurella multocida Toxin Interaction with Host Cells: Entry and Cellular Effects / Brenda A. Wilson and Mengfei Ho -- Swine Atrophic Rhinitis Caused by Pasteurella multocida Toxin and Bordetella Dermonecrotic Toxin / Yasuhiko Horiguchi -- The Pasteurella multocida Toxin: A New Paradigm for the Link Between Bacterial Infection and Cancer / Alistair Lax.
- 2013 ScienceDirectFederico Goodsaid, William B. Mattes.The Path from Biomarker Discovery to Regulatory Qualification is a unique guide that focuses on biomarker qualification, its history and current regulatory settings in both the US and abroad. This multi-contributed book provides a detailed look at the next step to developing biomarkers for clinical use and covers overall concepts, challenges, strategies and solutions based on the experiences of regulatory authorities and scientists. Members of the regulatory, pharmaceutical and biomarker development communities will benefit the most from using this book-it is a complete and practical guide to biomarker qualification, providing valuable insight to an ever-evolving and important area of regulatory science. Contains a collection of experiences of different groups taking different types of biomarkers to different levels of qualification and provides insightful case studies of an important area of regulatory science Focuses on practical advice, concepts, strategies and overall outcomes to support those working toward biomarker qualification for clinical use Offers a valuable resource for members of the regulatory, pharmaceutical and biomarker development communities.
- 2013 SpringerStephen T. Sonis, Dorothy M. Keefe, editors.
- 2014 SpringerNorbert Weiss, Alexandra Koschak, editors.Calcium ions represent Mother Nature's "ion-of-choice" for regulating fundamental physiological functions, as they initiate a new life at the time of fertilization and guide subsequent developmental and physiological functions of the human body. Calcium channels, which act as gated pathways for the movement of calcium ions across the membranes, play a central part in the initiation of calcium signals, and defects in calcium channel function have been found to result in a plethora of human diseases, referred to as the calcium channelopathies. Pathologies of Calcium Channels brings together leading international experts to discuss our current understanding of human diseases associated with the various calcium channels, from their molecular basis to potential future therapeutic targeting of calcium channels.
- 2015 SpringerGowraganahalli Jagadeesh, Pitchai Balakumar, Khin Maung-U, editors.
- 2011 SpringerHannsjörg W. Seyberth, Anders Rane, Matthias Schwab, editors.
- 2013 Wiley[edited by] Andrew E. Mulberg, Dianne Murphy, Julia Dunne, Lisa L. Mathis.Pediatric Drug Development, Second Edition, encompasses the new regulatory initiatives across EU, US and ROW designed to encourage improved access to safe and effective medicines for children. It includes new developments in biomarkers and surrogate endpoints, developmental pharmacology and other novel aspects of pediatric drug development.
- 2015 Wileyedited by Ben M. Dunn."This book details many of the problems and successes of peptides as potential drugs"--Provided by publisher.
- 2015 Springer Protocolsedited by Ratmir Derda.Design, synthesis, and application of OB2c combinatorial peptide and peptidomimetic libraries -- Synthesis of macrocyclic organo-peptide hybrids from ribosomal polypeptide precursors via cuAAC-/hydrazide-mediated cyclization -- Synthesis and screening of one-bead-one-compound cyclic peptide libraries -- Creating site-specific isopeptide linkages between proteins with the traceless staudinger ligation -- Macrocyclic templates for library synthesis of peptido-conjugates -- Synthesis and alkylation of aza-gly-pro building blocks of peptidomimetic libraries for developing prostaglandin f2alpha receptor modulators as therapeutics to inhibit preterm labor -- A fragment-based selection approach for the discovery of peptide macrocycles targeting protein kinases -- Peptide and peptide library cyclization via bromomethylbenzene derivatives -- Phage selection of bicyclic peptides based on two disulfide bridges -- De novo discovery of bioactive cyclic peptides using bacterial display and flow cytometry -- Chemical posttranslational modification of phage-displayed peptides -- Mapping protein-protein interactions with phage-displayed combinatorial peptide libraries and alanine scanning -- Identifying reactive peptides from phage-displayed libraries -- The best and the brightest: Exploiting tryptophan-sensitized tb(3+) luminescence to engineer lanthanide-binding tags -- Synthesis and cell-based screening of one-bead-one-compound peptide libraries -- Screening peptide array library for the identification of cancer cell-binding peptides -- Next-generation sequencing of phage-displayed peptide libraries -- Maleimide-based method for elaboration of cysteine-containing peptide phage libraries.
- 2008 Springer Protocolsedited by Laszlo Otvos.Peptide-based drug design : here and now / Laszlo Otvos, Jr. -- Strategies for the discovery, isolation, and characterization of natural bioactive peptides from the immune system of invertebrates / Philippe Bulet -- Sequence analysis of antimicrobial peptides by tandem mass spectrometry / Christin Stegemann and Ralf Hoffmann -- The spot technique : synthesis and screening of peptide macroarrays on cellulose membranes / Dirk F.H. Winkler and William D. Campbell -- Analysis of A[beta] interactions using ProteinChip technology / Eleni Giannakis ... [et al.] -- NMR in peptide drug development / Jan-Christoph Westermann and David J. Craik -- Molecular dynamics simulations of peptides / Jeffrey Copps, Richard F. Murphy and Sandor Lovas -- Short linear cationic antimicrobial peptides : screening, optimizing, and prediction / Kai Hilpert, Christopher D. Fjell and Artem Cherkasov -- Investigating the mode of action of proline-rich antimicrobial peptides using a genetic approach : a tool to identify new bacterial targets amenable to the design of novel antibiotics / Marco Scocchi ... [et al.] -- Serum stability of peptides / Håvard Jenssen and Stein Ivar Aspmo -- Preparation of glycosylated amino acids suitable for Fmoc solid-phase assembly / Mare Cudic and Gayle D. Burstein -- Synthesis of O-phosphopeptides on solid phase / David Singer and Ralf Hoffmann -- Peptidomimetics : Fmoc solid-phase pseudopeptide synthesis / Predrag Cudic and Maciej Stawikowski -- Synthesis of toll-like receptor-2 targeting lipopeptides as self-adjuvanting vaccines / Brandon Y. Chua, Weiguang Zeng and David C. Jackson -- Synthesis of a multivalent, multiepitope vaccine construct / Laszlo Otvos, Jr. -- Cysteine-containing fusion tag for site-specific conjugation of therapeutic and imaging agents to targeting proteins / Marina V. Backer ... [et al.].
- 2009 SpringerSusan Del Valle, Emanuel Escher, William D. Lubell, editors.
- 2005 CRCnetBASEedited by Robert L. Bronaugh, Howard I. Maibach.Also available: Print – 2005
- Percutaneous penetration enhancers chemical methods in penetration enhancement. Modification of the stratum corneum2015 SpringerNina Dragicevic, Howard I. Maibach, editors.
- 2016 SpringerNina Dragicevic, Howard I. Maibach, editors.NANOCARRIERS IN PENETRATION ENHANCEMENT -- Role Of Nanotechnology In Skin Delivery Of Drugs -- LIPID-BASED VESICLES -- Liposomes As Drug Delivery Systems In Dermal/Transdermal Drug Delivery (From The Beginning) -- Transfersomes For Enhanced Skin Permeation Of Drugs -- Mechanism Of Penetration Enhancement Of Ultra deformable Vesicles -- Enhanced Skin Permeation Using Ethosomes -- Invasomes-Vesicles For Enhanced Skin Delivery Of Drugs -- Penetration-Enhancer-Containing Vesicles For Cutaneous Drug Delivery -- Stratum Corneum Lipid Liposomes -- Vesosomes -- Surface-Charged Vesicles For Penetration Enhancement -- SURFACTANT-BASED VESICLES -- Niosomes And Pro-Niosomes For Enhanced Skin Delivery -- Novasomes For Enhanced Skin Delivery -- LIPID-BASED ICULATE CARRIERS (OR ICLES) -- Solid Lipid Nanoicles, Nano structured Lipid Carriers And Lipid Nano capsules For Topical Delivery -- POLYMER-BASED NANOCARRIERS (ICULATE CARRIERS) IN PENETRATION ENHANCEMENT -- Polymeric Nano (And Micro-) Particles As Carriers For Enhanced Skin Penetration (General) -- Polymeric Nanocapsules For Cutaneous Application -- Polymeric Micelles In Dermal/Transdermal Drug Delivery -- Dendrimers In Enhancing Skin Penetration -- Dendritic Core-Multishell (CMS) Nanotransporters For Skin Delivery -- NANOCRYSTALS IN PENETRATION ENHANCEMENT -- Nanocrystals For Enhanced Skin Delivery Of Drugs.
- Pharmaceutical accumulation in the environment : prevention, control, health effects, and economic impact2014 CRCnetBASEedited by Walter E. Goldstein.1. Introduction / Walter E. Goldstein -- 2. An insight into the discovery of the contamination of the environment and drinking water by pharmaceuticals / Thomas Heberer -- 3. Presence and fate of pharmaceuticals in the environment and in drinking water / James S. Smith Jr. -- 4. Occurrence, effects, and methods for antibiotics and illicit drugs in the environment / Tammy Jones-Lepp -- 5. Detection of pharmaceuticals in the environment : history of use as a forensic tool / Keir Soderberg and Remy J.-C. Hennet -- 6. Health impact of pharmaceuticals in the environment and in drinking water : potential for human and environmental risk / James S. Smith Jr. -- 7. Health impact of pharmaceuticals in the environment and in drinking water : analysis and research needs / Walter E. Goldstein -- 8. Effect of antibiotics on biological wastewater treatment processes / Olivier Potier, Jean-Noël Louvet, Christophe Merlin, Marie-Noëlle Pons, Dominique Dumas, and Walter E. Goldstein -- 9. Wastewater pharmaceuticals minimization : analysis of opportunities and costs / Walter E. Goldstein -- 10. Conclusions and recommendations, research opportunities, and implementation of measures to control environmental pharmaceuticals / Walter E. Goldstein.
- 2009 Springeredited by Carlos A. Guzman, Giora Z. Feuerstein.Translational medicine: a paradigm shift in modern drug discovery and development: the role of biomarkers / Mark Day, J. Lynn Rutkowski, and Giora Z. Feuerstein -- Natural products in drug discovery: present status and perspectives / Gabriella Molinari -- Protein pharmaceuticals: discovery and preclinical development / Davinder S. Gill -- The role of nanobiotechnology in drug discovery / Kewal K. Jain -- Conotoxin venom peptide therapeutics / Richard J. Lewis -- Shark novel antigen receptors: the next generation of biologic therapeutics? / Caroline Barelle, Davinder Gill, and Keith Charlton -- Immune interventions of human diseases through toll-like receptors / Cevayir Coban, Ken J. Ishii, and Shizuo Akira -- Genome-based vaccine development: a short cut for the future / Danilo Gomes Moriel ... [et al.] -- The antigenome: from protein subunit vaccines to antibody treatments of bacterial infections? / Carmen Giefing, Eszter Nagy, and Alexander von Gabain -- HSV as a vector in vaccine development and gene therapy / Peggy Marconi ... [et al.] -- Virus-like particles as a vaccine delivery system: myths and facts / Polly Roy and Rob Noad -- Applications of bacterial ghosts in biomedicine / Petra Lubitz, Ulrike Beate Mayr, and Werner Lubitz -- Immune modulators with defined molecular targets: cornerstone to optimize rational vaccine design / Thomas Ebensen and Carlos A. Guzmøn -- Innovative approaches to develop prophylactic and therapeutic vaccines against HIV/AIDS / Aurelio Cafaro ... [et al.] -- New strategies to overcome the drawbacks of currently available flu vaccines / Epifanio Fichera ... [et al.].
- 2015 CRCnetBASEedited by Heewon Lee.
- 2009. SpringerYi Lu, Ram I. Mahato, editors.
- 2008 ebrary2008 CRCnetBASEedited by Tony Kennedy.Strategic project management at the project level / Tony Kennedy -- Strategic project management at the portfolio level / Kevin Bilyard and Des Markland -- Project planning : from basic concepts to systems application / Carl A. Kutzbach, Carole Strong, and Sylvia Walker -- Project management of chemical, analytical, and formulation development / Dieter Krimmer -- Project management in exclusive synthesis / Lukas M.J. von Hippel -- Clinical trials--can they be project managed? / Les Rose -- Regulatory project management / Nicholas Wells -- Teams / Ralph White -- Project management and outsourcing drug development / Jon Court and Mark Fowler -- The project management function / Tony Kennedy.Also available: Print – 2008
- 2015 SpringerReem K. Al-Essa, Mohammed Al-Rubaie, Stuart Walker, Sam Salek.1. Overview of Medicines Regulatory Systems in the Gulf Region -- 2. The Regulatory Review Process in the Gulf Region -- 3. Regulatory Review Times in the Gulf Region -- 4. Quality Measures in the Gulf Regulatory Practices -- 5. The Current Status of the Common Technical Document -- 6. The Current Status of Drug Safety and Pharmacovigilance -- 7. The Centralized Regulatory Review in the Gulf Region -- 8. The Gulf States Assessment and Experience With the Centralised Procedure -- 9. The Pharmaceutical Companies Assessment and Experience With the Centralised Procedure -- 10. Proposal For an Improved Centralized Regulatory System -- 11. The Strategic Planning Process of the GCC Regulatory Authorities: Barriers And Solutions -- 12. The Regulatory Dilemma in the Gulf Region: The Way Forward.
- 2010 Springeredited by Kim Huynh-Ba.Contains proceedings of the AAPS Stability Workshop.
- 2007 ProQuest Safari[edited by] Alex Dmitrienko, Christy Chuang-Stein, Ralph D'Agostino.Statistics in drug development by Christy Chuang-Stein and Ralph D'Agostino -- Modern classification methods for drug discovery by Kjell Johnson and William Rayens -- Model building techniques in drug discovery by Kimberly Crimin and Thomas Vidmar -- Statistical considerations in analytical method validation by Bruno Boulanger, Viswanath Devanaryan, Walthère Dewé, and Wendell Smith -- Some statistical considerations in nonclinical safety assessment by Wherly Hoffman, Cindy Lee, Alan Chiang, Kevin Guo, and Daniel Ness -- Nonparametric methods in pharmaceutical statistics by Paul Juneau -- Optimal design of experiments in pharmaceutical applications by Valerii Fedorov, Robert Gagnon, Sergei Leonov, and Yuehui Wu -- Analysis of human pharmacokinetic data by Scott Patterson and Brian Smith -- Allocation in randomized clinical trials by Olga Kuznetsova and Anastasia Ivanova -- Sample-size analysis for traditional hypothesis testing: concepts and issues by Ralph G. O'Brien and John Castelloe -- Design and analysis of dose-ranging clinical studies by Alex Dmitrienko, Kathleen Fritsch, Janson Hsu, and Stephen Ruberg -- Analysis of incomplete data by Geert Molenberghs, Caroline Beunckens, Herbert Thijs, Ivy Jansen, Geert Verbeke, Michael Kenward, and Kristen Van Steen -- Reliability and validity: Assessing the psychometric properties of rating scales by Douglas Faries and Ilker Yalcin -- Decision analysis in drug development by Carl-Fredrik Burman, Andy Grieve, and Stephen Senn.
- 2011 SpringerAnthony J. Hickey, Hugh D.C. Smyth.
- 2007 CRCnetBASEManuchair Ebadi.
- 2011 SpringerAlan H.B. Wu, Kiang-Teck J. Yeo, editors.
- 2013 Springer Protocolsedited by Federico Innocenti, Ron H.N. van Schaik.Pharmacogenomics : historical perspective and current status / Rosane Charlab and Lei Zhang -- Denaturing high-performance liquid chromatography for mutation detection and genotyping / Donna Lee Fackenthal [and others] -- Clinical SNP detection by the smartAmp method / Toshihisa Ishikawa and Yoshihide Hayashizaki -- MALDI-TOF mass spectrometry / Dirk van den Boom, Matthias Wjst, and Robin E. Everts -- TaqMan® drug metabolism genotyping assays for the detection of human polymorphisms involved in drug metabolism / Toinette Hartshorne -- Pyrosequencing of clinically relevant polymorphisms / Cristi R. King and Sharon Marsh -- Pharmacogenetics using Luminex® xMAP® technology : a method for developing a custom multiplex single nucleotide polymorphism mutation assay / Gonnie Spierings and Sherry A. Dunbar -- Use of linkage analysis, genome-eide association studies, and next-generation sequencing in the identification of disease-causing mutations / Eric Londin [and others] -- GoldenGate genotyping assay : custom design, processing, and data analysis / Anna González-Neira -- Genome-wide gene expression profiling, genotyping, and copy number analyses of acute myeloid leukemia using affymetrix geneChips. / Mathijs A. Sanders and Peter J.M. Valk -- Epigenetic techniques in pharmacogenetics / Sandra G. Heil -- Plasmid derived external quality controls for genetic testing / Tahar van der Straaten and Henk-Jan Guchelaar -- Allelic imbalance assays to quantify allele-specific gene expression and transcription factor binding / Francesca Luca and Anna Di Rienzo -- SCAN : a systems biology approach to pharmacogenomic discovery / Eric R. Gamazon, R. Stephanie Huang, and Nancy J. Cox -- Methods to examine the impact of nonsynonymous SNPs on protein degradation and function of human ABC transporter / Toshihisa Ishikawa, Kanako Wakabayashi-Nakao, and Hiroshi Nakagawa -- In vitro identification of cytochrome P450 enzymes responsible for drug metabolism / Zhengyin Yan and Gary W. Caldwell -- In vitro and in vivo mouse models for pharmacogenetic studies / Amber Frick [and others] -- Hydrodynamic tail vein assay as a tool for the study of liver promoters and enhancers / Mee J. Kim and Nadav Ahituv -- Guide to the current web-based resources in pharmacogenomics / Dylan M. Glubb [and others] -- PharmGKB : the pharmacogenomics knowledge base / Caroline F. Thorn, Teri E. Klein, and Russ B. Altman -- Genetic databases in pharmacogenomics : the frequency of inherited disorders database (FINDbase) / Marianthi Georgitsi and George P. Patrinos -- Development of predictive models for estimating warfarin maintenance dose based on genetic and clinical factors / Lu Yang and Mark W. Linder -- Evidence based drug dosing and pharmacotherapeutic recommendations per genotype / Vera H.M. Deneer and Ron H.N. van Schaik.
- 2008 Springer ProtocolsNadine Cohen, editor.Challenges, opportunities, and evolving landscapes in pharmacogenomics and personalized medicine : an industry perspective / Nadine Cohen and Theresa Frangiosa -- Implementation of pharmacogenomic sample collection in clinical trials / Deborah Sokol Ricci and Monique Franc -- Pharmacogenomics : the regulatory environment and labeling implications / Myong-Jin Kim ... [et al.] -- Applications of pharmacogenomics in drug discovery / Duncan McHale -- Applications of pharmacogenomics in clinical trials / Monique Franc -- Pharmacogenomics applications in drug metabolism : from genotyping to drug label-challenges? / Ann K. Daly -- The genetics of adverse drug reactions : promises and problems / Martin Armstrong -- Strategies and resources for marker selection and genotyping in genetic association studies / Nicole Soranzo, Dong-Jing Fu, and Qingqin S. Li -- Study design and statistical issues in pharmacogenetics research : from candidate genes to genome-wide screens / Nicholas J. Schork, Nathalie Malo, and Eric J. Topol -- Holy SNP, Batman! / Reyna Favis -- Predictive biomarker classifiers in the design of pivotal clinical trials / Richard Simon -- Translation of biomarkers into clinical utility / William L. Trepicchio and George Mulligan -- Pharmacogenomic study feasibility assessment and pharmaceutical business decision-making / Monique Franc and Theresa Frangiosa -- Co-development of drugs and pharmacogenomics-based diagnostics in oncology / Jeffrey S. Ross -- Pharmacogenomics applications in epilepsy / Chantal Depondt -- Pharmacogenomics in Alzheimer's disease / Ramón Cacabelos -- Pharmacogenomics applications in psychiatric disorders / Todd Lencz and Anil K. Malhotra -- Pharmacogenomics in HIV disease / Amalio Telenti -- Pharmacogenomics and cardiovascular drugs / Gérard Siest ... [et al.] -- Pharmacogenomic applications in children / Susan F.A. Grant and Hakon Hakonarson -- Pharmacogenomics of rare and monogenic disorders / Paul D. Maher.
- 2012 Wileyedited by Loralie J. Langman, Amitava Dasgupta.Pharmacogenomics principles : introduction to personalized medicine / Parvaz Madadi, and Gideon Koren -- Traditional therapeutic drug monitoring and pharmacogenomics : are they complementary? / Christine Snozek, Loralie J. Langman, and Amitava Dasgupta -- Pharmacogenomics aspect of warfarin therapy / Matthew D. Krasowski -- Pharmacogenetics and cancer chemotherapy / Christine L.H. Snozek -- Pharmacogenomic considerations in anesthesia and pain management / Christine Formea, Wayne T. Nicholson -- Pharmacogenomics of immunosuppressants / Nicolas Picard and Pierre Marquet -- Pharmacogenomics of cardiovascular drugs / Linnea M. Baudhuin -- Pharmacogenomics aspect of antiretroviral therapy / Natella Y. Rakhmanina and John N. van den Anker -- Pharmacogenetics of psychoactive drugs / Jorge L. Sepulveda -- Pharmacogenomic aspects of adverse drug-drug interactions / Loralie J. Langman and Christine Snozek -- Microarray technology and other methods in pharmacogenomics testing / Jorge L. Sepulveda -- Pharmacogenetic testing in the clinical laboratory environment / Mark P. Borgman and Mark W. Linder.
- 2014 Springer Protocolsedited by Qing Yan, PharmTao, Santa Clara, CA, USA.From pharmacogenomics and systems biology to personalized care : a framework of systems and dynamical medicine / Qing Yan -- Translational bioinformatics approaches for systems and dynamical medicine / Qing Yan -- Whole blood transcriptomic analysis to identify clinical biomarkers of drug response / Grant P. Parnell and David R. Booth -- Diagnostic procedures for paraffin-embedded tissues analysis in pharmacogenomic studies / Raffaele Palmirotta [and six others] -- Approach to clinical and genetic characterization of statin-induced myopathy / QiPing Feng -- Pharmacogenomics of membrane transporters : a review of current approaches / Tristan M. Sissung [and four others] -- G protein-coupled receptor accessory proteins and signaling : pharmacogenomic insights / Miles D. Thompson [and three others] -- G protein-coupled receptor mutations and human genetic disease / Miles D. Thompson [and four others] -- Pharmacogenetics of the G protein-coupled receptors / Miles D. Thompson [and six others] -- Pharmacogenomics of heart failure / Anastasios Lymperopoulos and Faren French -- Pharmacogenomics in the development and characterization of atheroprotective drugs / Efi Valanti, Alexandros Tsompanidis, and Despina Sanoudou -- Management of side effects in the personalized medicine era : chemotherapy-induced peripheral neuropathy / Paolo Alberti and G. Cavaletti -- Pharmacogenomics of Alzheimer's disease : novel therapeutic strategies for drug development / Ramón Cacabelos [and four others] -- Pharmacogenetics of antipsychotic treatment in schizophrenia / Jennie G. Pouget and Daniel J. Müller / Pharmacogenetics of addiction therapy / David A. Nielsen [and three others] -- Pharmacogenetics in rheumatoid arthritis / Deepali Sen, Jisna R. Paul, and Prabha Ranganathan -- Pharmacogenetics of osteoporotic fractures / José A. Riancho and Flor M. Pérez-Campo -- Pharmacogenomics and pharmacoepigenomics in pediatric medicine / Barkur S. Shastry -- Pharmacogenomics in children / Michael Rieder.
- 2008 Springer Protocolsedited by Qing Yan.
- 2012 CRCnetBASE[edited by] Amitava Dasgupta, Loralie J. Langman.Ch. 1. Pharmacogenomics principles of alcohol and DOA / Christine L.H. Snozek and Loralie J. Langman -- ch. 2. Alcohol : use and abuse / Amitava Dasgupta -- ch. 3. Slate and trait makers of alcohol abuse / Joshua Bornhorst ... [et al.] -- ch. 4. Introduction to drugs of abuse / Larry Broussard and Catherine Hammett-Stabler -- ch. 5. Pharmacogenomics of amphetamine and related drugs / Steven C. Kazmierczak -- ch. 6. Pharmacogenomics of cocaine / Loralie J. Langman and Christine L.H. Snozek -- ch. 7. Genetic aspect of marijuana metabolism and abuse / Pradip Datta -- ch. 8. Genetic aspect of opiate metabolism and addiction / Jorge L. Sepulveda -- ch. 9. Pharmacogenomics aspects of addiction treatment / F. Gerard Moeller -- ch. 10. Methodologies in pharmacogenetics testing / Jorge L. Sepulveda.
- 2013 Wileyedited by Toshihisa Ishikawa, Richard B. Kim, Jörg König.Introduction to pharmacogenomics of drug transporters / Marianne K DeGorter and Richard B Kim -- ADME pharmacogenomics in drug development / Liangfu Chen and Joseph W. Polli -- Regulatory perspective on pharmacogenomics of drug metabolizing enzymes and transporters / Lei Zhang [and others] -- The pharmacogenomics of membrane transporters project / Sook Wah Yee, Deanna L. Kroetz, Kathleen M. Giacomini -- Emerging new technology of SNP typing / Toshihisa Ishikawa and Yoshihide Hayashizaki -- Chapters 6: OATP1A2, OAT1 and OAT3 / Rommel G. Tirona -- OATP1B1, OATB1B3 and OATP2B1 / Jorg Konig and Martin Fromm -- OCT (SLC22A) and OCTN families / Sophie L. Stocker [and others] -- MATE (SLC47) family / Atsushi Yonezawa and Ken-ichi Inui -- PEPT (SLC15A) family / Tomoko Sugiura [and others] -- Nucleoside transporters (SLC28 and SLC29) family / Míriam Molina-Arcas -- Maral pastor-anglada -- P-glycoprotein (MDR1/ABCB1) / Ingolf Cascorbi -- Bile salt export pump BSEP (ABCB11) : role in liver physiology and liver disease / Gerd Ullak-Kublick and Bruno Stieger -- BCRP (ABCG2) / Agnes Basseville [and others] -- MRP2 (ABCC2) and MRP3 (ABCC3) / Anne T. Nies -- MRP4 (ABCC4) / Satish B. Cheepala, Mugdha Sukthankar, John D. Schuetz -- MRP8 (ABCC11) / Yu Toyoda, Toshihisa Ishikawa -- Future perspectives / Toshihisa Ishikawa, Joseph Ware.
- 2006 SpringerPeter L. Bonate.
- 2011 SpringerPeter L. Bonate.
- 2006 WileyDennis A. Smith, Han van de Waterbeemd, and Don K. Walker.ch. 1. Physicochemistry -- ch. 2. Pharmacokinetics -- ch. 3. Absorption -- ch. 4. Distribution -- ch. 5. Clearance -- ch. 6 Renal clearance -- ch. 7. Metabolic (hepatic) clearance -- ch. 8. Toxicity -- ch. 9. Inter-species -- ch. 10. High(er) throughput ADME studies.
- 2008 CRCnetBASEedited by Steven B. Karch.
- 2011 SpringerPeter L. Bonate, Danny R. Howard, editors.
- 2016 SpringerHector O. Ventura, editor.This volume reviews potential future therapies for heart failure, with a particular focus on ambulatory acute decompensated heart failure and the transitions from therapies in the acute setting to chronic management. Although in the developed world the incidence of and mortality from coronary heart disease and stroke have been declining over the last 15 years, heart failure is increasing in incidence, prevalence and overall mortality, despite advances in the diagnosis and management of the condition. Pharmacologic Trends of Heart Failure builds on the current understanding of pathophysiological mechanisms and insights gained from previous studies of therapeutic interventions. It is designed to establish the baseline level of knowledge that a cardiovascular professional needs to know on a day-to-day basis.
- 2016 SpringerParimelazhagan Thangaraj.1. Ethnobotanical study -- 2. Pharmacognostical studies -- 3. Extraction of bioactive compounds -- 4. Preliminary phytochemical studies -- 5. Proximate composition analysis -- 6. Mineral quantification -- 7. Anti-nutritional factors -- 8. Quantification of secondary metabolites -- 9. In vitro antioxidant assays -- 10. In vitro antihaemolytic activity -- 11. Antimicrobial activity -- 12. In vitro anthelmintic assay -- 13. Toxicity studies -- 14. In vivo antioxidant assays -- 15. Analgesic activity -- 16. Anti-inflammatory activity -- 17. Antipyretic activity -- 18. Inflammatory bowel disease -- 19. In vitro anti-arthritic activity -- 20. Anti-diarrhoeal activity -- 21. Anti-ulcer activity -- 22. Hepatoprotective activity -- 23. Anti-diabetic activity -- 24. Evaluation of anti-diabetic property on streptozotocin-induced diabetic rats -- 25. In vivo wound healing studies -- 26. Determination of cytotoxicity -- 27. Induction of apoptosis -- 28. Anti-tumour activity -- 29. Protein bioavailability in animal model -- 30. Detection of phenolic and flavonoid compounds using high performance thin layer chromatography (HPTLC) -- 31. Isolation of compounds -- 32. Molecular docking of bioactive compounds against BRCA and COX proteins -- Index.
- 2015 SpringerYoo Keun Chan, Kwee Peng Ng, Debra Si Mui Sim, editors.This book is the 4th in a series of Acute Care books written with the aim to address the NEEDS of health care providers when handling the acutely ill patients. Globally it has become apparent that the study of pharmacology and subsequent clinical training has not always adequately equipped young doctors with the ability to administer drugs to their patients safely and confidently, particularly in the critically ill patient. Compounding this issue is the lack of resource material related to these pharmacological concepts contained in one book that can help health care providers to understand and manage drug therapy in the acute situation. In spite of progressively newer and more developed protocols, guidelines, algorithms and many other books addressing the technical aspects of what needs to be done, most health care providers still find it difficult to grasp the basic pharmacological knowledge and rationally deliver the CARE that is required in the acute phase of patient management. The editors/authors have therefore aimed for a book that highlights topics and pharmacological issues pertinent to management of patients in their hour of need. This is a multi-author book but the style has been guided by 3 editors. The editors have used a different perspective? that of normalizing abnormal physiological processes with pharmacological agents? to address the GAPS in a bedside to bench approach. The details are pared down but important principles/concepts are emphasized.
- 2016 SpringerDimos D. Mitsikostas, Koen Paemeleire editors.1. Headache classification -- 2. Epidemiology of headache disorders -- 3. General principles of pharmacotherapy for headache disorders.- 4. Placebo and nocebo effects -- 5. Review of existing guidelines -- 6. Acute migraine treatment -- 7. Preventive (episodic) migraine treatment -- 8. Drug treatment for chronic migraine -- 9. Drug treatment for episodic and chronic tension-type headache (TTH) -- 10. Cluster headache: acute and transitional treatment -- 11. Cluster headache: preventive treatment -- 12. Pharmacotherapy for other primary headache disorders -- 13. Pharmacotherapy for primary headache disorders in children -- 14. Pharmacological strategies in the prevention of migraine in children -- 15. Pharmacotherapy for primary headache disorders during pregnancy and lactation -- 16. Pharmacotherapy for primary headache disorders in the elderly -- 17. Acute and chronic posttraumatic headache -- 18. Headache attributed to low and increased CSF pressure -- 19. Medication-overuse headache -- 20. Painful cranial neuropathies -- 21. Dental and Musculoskeletal Pain -- 22. Post-traumatic neuropathies and Burning mouth syndrome.
- 2008 Springeredited by A. Claudio Cuello.
- 2013 SpringerGabriela Hrckova, Samuel Velebny.The natural world with a large number of terrestrial and marine plants and lower organisms is a great source of bioactive compounds historically used as remedies in various diseases. Within the last decade, such compounds became more attractive targets for pharmacologists and the pharmaceutical industry in drug development projects. This volume presents the pharmacological potential of chemically defined natural compounds obtained from plants, fungi, algae and cyanobacteria with antiparasitic activity, that have been tested against various endo-parasitic protozoan and helminth species. --Source other than Library of Congress.
- 2014 SpringerPablo Avanzas, Peter Clemmensen, editors.Cardiovascular pharmacotherapy is a fast-moving and complex discipline within cardiology in general. New studies, trials and indications are appearing on a regular basis. This series, and this particular title within the series, is designed to establish the baseline level of knowledge that a cardiovascular professional needs to know on a day-to-day basis. The information within is designed to allow readers to learn quickly and with certainty the mode of action, the possible adverse effects, and the management of patients prescribed these drugs.
- 2015 SpringerPablo Avanzas, Juan Carlos Kaski, editors.This book describes the clinical challenge currently posed by stable angina pectoris and provides guidance for those making clinical decisions regarding its pharmacological treatment. The importance of providing effective treatment is beyond dispute and this book deals with the most relevant aspects related to its pharmacological treatment. The pathogenesis of myocardial ischemia as the basis for rational treatment of angina is discussed thoroughly together with all major management goals including optimal symptom control and the secondary prevention of serious cardiovascular events. Pharmacological Treatment of Chronic Stable Angina Pectoris provides a clear description of the mechanisms of action and clinical indications of available anti-angina drugs and strategies for the use of novel pharmacological agents. It also includes a critical appraisal of the major management guidelines, which will assist the reader to interpret current evidence and provide the most appropriate forms of treatment. The ongoing controversy regarding medical therapy versus myocardial revascularization for the management of stable angina pectoris is also addressed. This eminently practical book will help guiding the reader through the complexities of the field and will be highly appreciated by clinicians, clinical cardiologists and cardiology trainees alike.
- 2009 WHO
- A to Z drug facts — Development of innovative drugs via modeling with MATLAB : a practical guide (135)
- Development of novel vaccines : skills, knowledge, and translational technologies — Kidney-- toxicological assessment (135)
- Kinase inhibitors : methods and protocols — Pharmacological treatment of mental disorders in primary health care (135)
- Pharmacology : PreTest self-assessment and review. 12th ed. — WHO guidelines on safety monitoring of herbal medicines in pharmacovigilance systems (133)
- Harrison's Principles of Internal Medicine
- AAP Red Book Online
- Robbins & Cotran Pathologic Basis of Disease
- Sabiston Textbook of Surgery
- Nelson's Textbook of Pediatrics
- Surgical Exposures in Orthopaedics
- Mandell, Douglas, & Bennett's Principles & Practice of Infectious Diseases
- Red Book Online
- ICU Book
- Primary Care Medicine
- Campbell-Walsh Urology
Access restricted to Stanford community
Shortcut to Licensed Content
TO INSTALL, DRAG THIS BUTTON to your browser Bookmarks or Tools Bar.
Bookmark on Other Websites
- TO INSTALL, RIGHT CLICK this button.
- Select "Add to Favorites" (click “Continue” if you see a security alert)
- From the "Create in" menu, select “Favorites Bar” (IE8, IE9) to install
- Once installed it will look like this
- Click "Bookmark on Lane" to bookmark any webpage
- Your saved bookmark will appear on this page
Can't find it?
Look if we have it in print
- Springer Protocols
- Lange Series
- National Academy Press
- NCBI Bookshelf
- Thieme Atlases
A repository of medical knowledge from internal medicine, cardiology, genetics, pharmacy, diagnosis and management, basic sciences, patient care, and more.
Continuously expanding, all databases in the repository contain the latest editions of selected medical titles.MicroMedex: Premier pharmaceutical information source containing multiple databases and drug reference tools. Of particular value is DRUGDEX Evaluations, one of the most comprehensive drug sources available.DynaMed is a clinical information resource used by physicians to answer clinical questions quickly and easily at the point of care. Topics are updated daily as new evidence becomes available.Scopus is the largest abstract and citation database of peer-reviewed literature: scientific journals, books and conference proceedings.A drug information resource containing: American Hospital Formulary System (AHFS), drug formulary for Lucile Packard Children's Hospital (LPCH) and Stanford Hospital & Clinics (SHC), Lexi-Drugs (adverse reactions, dosage and administration, mechanism of action, storage, use, and administration information), Lexi-Calc, Lexi-ID, Lexi-I.V. Compatibility (King Guide), Lexi-Interact, and Lexi-PALS.Cumulative Index to Nursing and Allied Health Literature (CINAHL) contains coverage of nursing and allied health literature.A knowledge database that provides access to topic reviews based on over 6000 clinically relevant articles. The evidence-based content, updated regularly, provides the latest practice guidelines in 59 medical specialtiesProvides critical assessments of systematic reviews compiled from a variety of medical journals.Selects from the biomedical literature original studies and systematic reviews that are immediately clinically relevant and then summarizes these articles in an enhanced abstract with expert commentary.
Multidisciplinary coverage of over 10,000 high-impact journals in the sciences, social sciences, and arts and humanities, as well as international proceedings coverage for over 120,000 conferences.
Includes cited reference searching, citation maps, and an analyze tool.
Features systematic reviews that summarize the effects of interventions and makes a determination whether the intervention is efficacious or not.
Cochrane reviews are created through a strict process of compiling and analyzing data from multiple randomized control trials to ensure comprehensiveness and reliability.Provides systematic coverage of the psychological literature from the 1800s to the present through articles, book chapters and dissertations.BMJ Clinical Evidence. A clinical information tool built around systematic reviews summarizing the current state of knowledge about prevention and treatment of clinical conditions.PIER (Physicians' Information and Education Resource) is a Web-based decision-support tool designed for rapid point-of-care delivery of up-to-date, evidence-based guidance for primary care physicians.Cochrane Central Register of Controlled Trials (CENTRAL) provides access to 300,000 controlled trials that have been identified the Cochrane Collaboration.Provides drug information targeted for patients.A continually updating drug monograph.The National Guideline Clearinghouse (NGC): A comprehensive database of evidence-based clinical practice guidelines and related documents.MedlinePlus: A repository of health information from the National Library of Medicine. Links are from trusted sites. No advertising, no endorsement of commercial companies or productsLPCH CareNotes via MicroMedex: Patient education handouts customized by LPCH clinical staffMicromedex Lab Advisor: Evidence based laboratory test informationA drug database organized by generic name, trade name and drug class.LPCH / Stanford Hospital Formulary.A goldmine of trusted consumer health information from the world's largest medical library.A trusted source of expert advice for and about kids, providing the information necessary to help patients and parents understand their unique needs.Provides patient handouts from the American Academy of Family Physician.Access to the Stanford Health Library for patients.Lane provides access to over 5,000 eBooks many of which provide helpful background material that will prepare you to better tackle primary literature.
Largest, broadest eBook package; covers all sciences, as well as technology (including software), medicine, and humanities.
In addition to covering Wiley and Springer, MyiLibrary is also the only provider for Oxford and Cambridge University Press titles. No seat restrictions.A collection of biomedical books that can be searched directly by concept, and linked to terms in PubMed abstracts.
A web-based, decision support system for infectious diseases, epidemiology, microbiology and antimicrobial chemotherapy. The database, updated weekly, currently includes 337 diseases, 224 countries, 1,147 microbial taxa and 306 antibacterial (-fungal, -parasitic, -viral) agents and vaccines.
Over 10,000 notes outline the status of specific infections within each country.
Provides online, full-text access to Springer's journal titles as well as journals from other publishers.
Subjects include: life sciences, chemical sciences, environmental sciences, geosciences, computer science, mathematics, medicine, physics and astronomy, engineering and economics. Also includes eBooks.Collection of over 8 thousand fulltext titles in engineering, math, and basic and applied biomedical research. Coverage is from 1967 to the present.A library of ebooks on a wide array of topics, digitized and made available online in conjunction with the original publishers.